• ICKSH 2019

MARCH 14 - 16, 2019

Grand Walkerhill Hotel, Seoul, Korea

Program Book



2019 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE & 60th ANNUAL MEETING

The Korean Society of Hematology

CONTENTS

02	Welcome Message
03	Organizing Committee
04	Program-at-a-Glance
15	Floor Plan
18	General Information
20	Speaker Information
21	Social Program
22	Sponsors (Acknowledgement)
24	Exhibition
28	Plenary Lectures
31	Daily Program
53	Posters

WELCOME MESSAGE

Dear Colleagues,

On behalf of the Organizing Committee, it is our great honor and pleasure to invite you to the 2019 KSH International Conference & the 60th Annual Meeting, hosted by the Korean Society of Hematology (KSH), which will be held in Seoul, Korea from March 14 to 16, 2019.

The Korean Society of Hematology successfully held the first ICKSH in conjunction with BTG last year, surpassing all expectations. Now, the Organizing Committee is positioning the KSH to lead the field of hematologic diseases through the relationships and cooperation of many countries by sharing our treatment technology with the world. The ICKSH will offer the unique opportunity to learn about the latest findings and research from renowned specialists as well as to exchange ideas and information on the most recent trends.

Our programs will include benign hematologic diseases, various types of hematologic malignancies, coagulation/thrombosis related disorders and transfusion medicine through plenary lectures, as well as scientific and education sessions. In addition, a variety of stimulating social programs has been planned so participants can enjoy the fascinating Korean culture and share our warm spirit of friendship. We welcome you all and hope you enjoy ICKSH 2019 in Seoul, Korea.



C). Park

Chan-Jeoung Park, M.D., Ph.D.
Congress Chair
The Korean Society of Hematology



arolin

Bin Cho, M.D., Ph.D.
President
The Korean Society of Hematology

ORGANIZING COMMITTEE

Congress Chair

Chan-Jeoung Park

University of Ulsan, College of Medicine

Secretary General

Jin Seok Kim

Yonsei University, College of Medicine

Scientific Program Committee Chair

Hyoung Jin Kang

Seoul National University, College of Medicine

International Cooperation Committee Chair

Hee-Je Kim

College of Medicine, The Catholic University of Korea

Education and Training Committee Chair

Dae Young Zang

Hallym University, College of Medicine

President

Bin Cho

College of Medicine, The Catholic University of Korea

Vice Secretary General

Yong Park

Korea University, College of Medicine

Finance Committee Chair

Seongsoo Jang

University of Ulsan, College of Medicine

Medical Policy Committee Chair

Joon Seong Park

Ajou University, School of Medicine

Public Relations Committee Chair

Hyeon Jin Park

National Cancer Center

Time	VISTA 1	VISTA 2	VISTA 3	GRAND HALL
08:00- 09:00		Regist	tration	
09:00	OPENING REMARKS			
09:00- 10:30	JS01 KAI-KSH JOINT SYMPOSIUM Immunotherapeutics in Blood Disease	SS01 Bone Marrow Failure		
	IL-7-hyFc, a long-acting recombinant IL-7 protein, generates anti-tumor activity by modulating both adaptive and innate immune cells in the tumor microenvironment (Seung-Woo Lee, Korea)	Paroxysmal nocturnal hemoglobinuria in bone marrow failure (Jun Ho Jang, Korea)		
	Towards next-generation CAR-T cell therapy for cancer (Chan Hyuk Kim, Korea)	Germline mutations in inherited bone marrow failure (Jean Soulier, France)		
	Immunotherapeutics in blood disease: Cytotoxic T lymphocyte therapy (Hyewon Lee, Korea)	Telomere length and somatic mutations in aplastic anemia (Dong Soon Lee, Korea)		
	Immune checkpoint inhibitor in lymphoma (Yoon Seok Choi, Korea)			
10:30- 10:45	Coffee Break			
10:45- 11:45	G	PL01 ene Therapy in Hematolo	gy	
	Applicat	ion of CRISPR/Cas-9 in blood (Matthew H. Porteus, USA)	d disease	
	Gene therapy for hemophilia-will there be a new era in hemophilia treatment? (Katherine Ann High, USA)			

Time	VISTA 1	VISTA 2	VISTA 3	GRAND HALL	
11:45- 12:45	PRI	PRESIDENTIAL SYMPOSIUM			
		Stem cells in human AML (Ravi Majeti, USA)			
	Precision medici	ne in pediatric acute lympho (Ching-Hon Pui, USA)	oblastic leukemia		
12:45- 13:40	[Luncheon] LS01 U NOVARTIS	[Luncheon] LS02 AMGEN		[Luncheon] LS03 Roche	
	Treatment free remission in CML: Promise and challenges (Adam Mead, UK)	Optimal treatment sequencing for patients with relapsed/refractory multiple myeloma (Ajai Chari, USA)		Current issues in the treatment of B-cell lymphoma (Seok Jin Kim, Korea)	
13:40- 14:40	AS01 Lymphoid	AS02 Myeloid			
	Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia- Korean perspectives (Young Rok Do, Korea)	CML in Philippines (Priscilla B. Caguioa, Philippines)			
	Hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia in Taiwan - on Behalf of TSBMT (Tran-Der Tan, Taiwan)	Outcome of allogeneic hematopoietic stem cell transplantation for SAA and PNH at Vietnam national institute of haematology and blood transfusion (Binh Thi Thanh Vo, Vietnam)			
	Adult ALL in Malaysia (Sen Mui Tan, Malaysia)	Hemoglobinopathy in Thailand (Duantida Songdej, Thailand)			

Time	VISTA 1	VISTA 2	VISTA 3	GRAND HALL	
14:40- 14:55	Coffee Break				
14:55- 16:25	JS02 KOGO-KSH JOINT SYMPOSIUM Genomics for Precision Hematology	SS02 Multiple Myeloma	SS03 Transplantation/ Cell Therapy	ES01 Iron Metabolism	
	Understanding angioimmunoblastic T-cell lymphoma: From genomics to animal pathology (Jaesang Kim, Korea)	Immunological weapons against multiple myeloma (Je-Jung Lee, Korea)	Thymidine kinase cell therapy (Maria Chiara Bonini, Italy)	Iron metabolism in hemoglobinopathies (Vip Viprakasit, Thailand)	
	Genomic pathogenesis of Epstein–Barr virus (EBV)- induced diffuse large B cell lymphoma (Sung-Yup Cho, Korea)	Roles of bone marrow microenvironment in clonal evolution and drug resistance of multiple myeloma (Yusuke Furukawa, Japan)	Updates on CART cell therapy for multiple myeloma (Jesús G. Berdeja, USA)	Deferasirox for iron overload patients: Preserving organ functions (Norbert Gattermann, Germany)	
	Current status of precision hematology (Young-Uk Cho, Korea)	Antigen-mediated regulation in myeloma (Madhav V. Dhodapkar,	Accelerating personalization of immune therapies for blood cancers	Management of iron overload in MDS (Heather Alice Leitch, Canada)	
	Clinical application of personalized medicine for AML (Joon-ho Moon, Korea)	USA)	(Larry W. Kwak, USA)	Cariaday	
16:25- 16:40	Break				

Time	VISTA 1	VISTA 2	VISTA 3	GRAND HALL	
16:40- 18:10	SS04 Myeloproliferative Neoplasm	SS05 Bleeding Disorder/ Thrombosis	SS06 Pediatric Disease	ES02 Indolent Lymphoma: From Genetics to the Clinic	
	Genetic causes of myeloproliferative diseases: Stratification of patients and new therapeutic targets (Robert Kralovics, Austria)	Progress in gene therapy for hemophilia A and B (Glenn F. Pierce, USA)	Inherited hematologic malignancies (Lucy Ann Godley, USA)	Mantle cell lymphoma -from the clinic to genetics (Mats Jerkeman, Sweden)	
	Molecular mechanism of MPN development by mutant calreticulin (Norio Komatsu, Japan)	Individualized treatment for hemophilia: Population pharmacokinetics approach (Cindy H.T. Yeung, Canada)	GATA2 deficiency: How to make the diagnosis? How to treat it? (Jean Donadieu, France)	From genetics to the clinic: Follicular lymphoma (Gilles Salles, France)	
	Interferon in myeloproliferative neoplasms (Jean-Jacques Kiladjian, France)	Mechanisms of cancer- associated thrombosis (Nigel Mackman, USA)	Roles of monosomy 7 and SAMD9/SAMD9L mutations in myeloid leukemogenesis (Hirotaka Matsui, Japan)	From genetics to the clinic of chronic lymphocytic leukemia (Wei Xu, China)	
18:10- 18:30	Break				
18:30- 20:00	WELCOME RECEPTION (Re: BAR, Vista Walkerhill Seoul, 1F)				

Time	VISTA 1	VISTA 2	VISTA 3	
08:00- 09:00		Registration		
09:00- 10:30	JS03 EHA-KSH JOINT SYMPOSIUM I Multiple Myeloma	SS07 Benign Hematology	SS08 Histiocytosis	
	Monoclonal antibodies in the treatment of multiple myeloma (Francesca Maria Gay, Italy)	EuroBloodNet: The rare anaemia disorders European epidemiological platform (María del Mar Mañú Pereira, Spain)	Langerhans cell histiocytosis 2019: New insights and opportunities (Carl E. Allen, USA)	
	Treatment for advanced multiple myeloma in Korea (Chang-Ki Min, Korea)			
	Experimental therapy except monoclonal antibodies (Francesca Maria Gay, Italy)	Clinical utility of high-throughput sequencing for the diagnosis of hereditary hemolytic anemia (Myungshin Kim, Korea)	Treatment of HLH - today and tomorrow (Jan-Inge Henter, Sweden)	
	Clinical outcomes of cytogenetic high-risk multiple myeloma in Korea (Kihyun Kim, Korea)	The molecular spectrum of hemoglobinopathy: Thalassemia and Hb variants (Cornelis Leonard Harteveld, The Netherlands)	Genetic studies on the hemophagocytic lymphohistiocytosis (HLH) in Korea (Jong Jin Seo, Korea)	
10:30- 10:45	Coffee Break			
10:45- 11:45		PL02 Clinical Hematology		
	Breakt	hroughs in the treatment of aplastic a (Neal Stuart Young, USA)	nemia	

Time	GRAND HALL	WALKER HALL 1	WALKER HALL 2
08:00- 09:00	Registration		
09:00- 10:30	ES03 Acute Lymphoblastic Leukemia		
	Pharmacogenetics in patients with childhood acute lymphoblastic leukemia (Yoichi Tanaka, Japan)		
	Recent advances in the treatment of adult ALL (Won Sik Lee, Korea)		
	Mutational landscape of ALL: Next- generation sequencing-based mutations scanning strategy (Seung-Tae Lee, Korea)		
10:30- 10:45	Coffee Break		
10:45- 11:45			

Time	VISTA 1	VISTA 2	VISTA 3	
11:45- 12:45	AS03 Special Report from JSH, CAH, KSH			
Developing strategies to improve efficacy and safety of chimeric antigen receptor cell therapy (Kyung-Nam Koh, Korea)		POSTER PRE	DECENTATION	
	New insights into poor hematopoietic reconstitution after allo-HSCT (Yuan Kong, China)	(Exhibition Hall, B3) fiter tion		
	Targeting hotspot RHOA mutation in angioimmunoblastic T-cell lymphoma (Shigeru Chiba, Japan)			
12:45- 13:40	[Luncheon] LS04 Bristol-Myers Squibb	LS04 tol-Myers Squibb CML management and (Andrea Gallamini, France) A new paradigm shift in frontline treatment of hodgkin lymphoma (Andrea Gallamini, France)		
	Advances of CML management and the prospects for the future (Susanne Saußele, Germany)			
13:40- 13:50	Coffee Break			


Time	GRAND HALL	WALKER HALL 1	WALKER HALL 2
11:45- 12:45		POSTER PRESENTATION (Exhibition Hall, B3)	
12:45- 13:40	[Luncheon] LS06 KYOWA KIRIN		
	The role of the darbepoetin alfa of the treatment for low-risk of MDS (Jun Ho Jang, Korea)		
13:40- 13:50	Coffee Break		

Time	VISTA 1	VISTA 2	VISTA 3	
13:50- 15:05	OP01 AML/MDS	OP02 ALL	OP03 Lymphoma	
15:05- 16:20	OP07 AML/MDS	OP08 Multiple Myeloma	OP09 Lymphoma/Histiocytosis	
16:20- 16:35		Break		
16:35- 18:05	SS09 Future ICT based Medicine	SS10 Acute Myeloid Leukemia/ Myelodysplastic Syndromes	SS11 Chronic Myeloid Leukemia	
	Deep learning for CRISPR-Cpf1 research (Sungroh Yoon, Korea)	Genomics of core-binding factor AML (Nicolas Duployez, France)	Is chronic myeloid leukemia a single hit disorder?: Evidence from next-generation sequencing data (Dennis Kim, Canada)	
	Precision dinner: Genomes and health records (Ju Han Kim, Korea)	Precision medicine in AML in the era of novel agents (Gail J. Roboz, USA)	NGS-based ABL1 kinase domain mutation detection (Simona Soverini, Italy)	
	Connected health and wellness journey (Jack Ahn, USA)	Incorporation of molecular assessments in risk stratification for myelodysplastic syndromes: Ready for prime time? (Amer M. Zeidan, USA)	Precision medicine and immunity in CML (Satu Mustjoki, Finland)	
18:05- 18:30		Break		
18:30- 20:00	GALA DINNER (Walkerhill Theatre, B1)			

Time	GRAND HALL	WALKER HALL 1	WALKER HALL 2
13:50- 15:05	OP04 Laboratory Hematology/Cell Therapy/Hematopoiesis Stem Cell Biology/Basic Science	OP05 Bone Marrow Failure Syndrome/ Anemia/Cytopenia	OP06 Transplantation
15:05- 16:20	OP10 MPNs/CML	OP11 Platelet/Hemostasis/ Thrombosis	OP12 Transplantation
16:20- 16:35	Break		
16:35- 18:05	ES04 Coagulation		
	Early "Goal-directed Coagulation Therapy" approaches for the management of acute trauma- hemorrhage and trauma-induced coagulopathy (Marc Guido Maegele, Germany)		
	Clinical application of clot waveform analysis in hemophilia treatment (Keiji Nogami, Japan)		
	Thrombin generation assay (Bas de Laat, The Netherlands)		
18:05- 18:30	Break		
18:30- 20:00	GALA DINNER (Walkerhill Theatre, B1)		

Time	VISTA 1	VISTA 2	VISTA 3	GRAND HALL
07:30- 08:30				
08:30- 09:00	WORKING PARTY REPORTS			
09:00- 10:30	JS04 EHA-KSH JOINT SYMPOSIUM II Chronic Myelogenous Leukemia	SS12 Childhood Acute Lymphoblastic Leukemia	SS13 Lymphoma	SS14 Advances in Technology
	Europe's experience of treatment-free remission in CML (Susanne Saußele, Germany)	Treatment of childhood ALL with IKZF1 deletion (Malaysia-Singapore ALL 2010 Study) (Allen Yeoh Eng Juh,	Pathogenesis of EBV-associated lymphoproliferative disorders (Hiroshi Kimura, Japan)	Droplet microfluidics in antibody discovery, immune repertoire sequencing and personalized cancer therapy (Christoph A. Merten, Germany)
	Korea's experience of treatment-free remission in CML (Hawk Kim, Korea)	Singapore)		
	TKI-related cardiovascular toxicities in Europe (Susanne Saußele, Germany)	Multicenter clinical trial of pediatric acute lymphoblastic leukemia in China: CCLG 2008 study (Chi-kong Li, Hong Kong)	Molecular understanding of peripheral T-cell lymphoma (Javeed Iqbal, USA)	Applications of single- cell mass cytometry in hematologic malignancies (Gregory Behbehani, USA)
	Long-term safety of tyrosine kinase inhibitors in chronic myeloid leukemia patients (Jee Hyun Kong, Korea)	Recent updates of prospective trials for ALL in Japan (Yasuhiro Okamoto, Japan)	Clinical application of cell- free DNA in lymphoma (Seok Jin Kim, Korea)	Prediction of acute myeloid leukemia risk in healthy individuals (Liran I. Shlush, Israel)
10:30- 10:45				
10:45- 11:45	Geno			
	The new ge			
	Genetic basis a			
11:45- 12:30	AWARD CEREMONY & CLOSING (Vista 1, B2)			

FLOOR PLAN Side View



4F PINE, OAK

Meeting Room

1F	WALKER HALL 1, 2 Oral Session	RE:BAR Welcome Reception	
B1	WALKERHILL THEATRE Gala Dinner	GRAND HALL Scientific Session Exhibition (Lobby) Coffee & Tea (Lobby) Event & Photo Zone (Lobby) Meeting Room	IDA 1, 2 ICKSH OC Room VIP Room Preview Room Kit & Cloak Desk (Lobby)
B2	VISTA HALL Scientific Session Opening / Closing Ceremony Plenary Session	VISTA HALL LOBBY Exhibition Registration Desk Coffee Break	


B3 EXHIBITION HALL


Exhibition Posters

Coffee

Internet Lounge


FLOOR PLAN






FLOOR PLAN

B2







GENERAL INFORMATION

Registration

All participants are required to check in at the registration desk to pick up their name badge. Badges must be worn during all scientific sessions and social programs.

LOCATION	Vista Lobby (B2)		
OPERATION HOURS	March 14 (Thu) 08:00 - 18:00		
	March 15 (Fri) 08:00 - 18:00		
	March 16 (Sat) 08:00 - 12:30		

On-site Registration Fees

General	USD 200
Resident / Trainee / Nurse / Student	USD 100

+ Registration fees include:

Participation in all scientific sessions, exhibition, satellite symposium including lunch, coffee breaks, conference kit, welcome reception and gala dinner.

+ Conference Kit will be distributed with your name badge at the Kit desk (B1). The kit includes a Program book and Abstract book.

Lunch

Lunch boxes will be provided during the satellite symposium. Please bring the lunch coupon in your name badge.

LOCATION	Vista Hall 1(B2), Vista Hall 2+3 (B2), Grand Hall (B1)
OPERATION HOURS	March 14 (Thu) 12:45 - 13:40
	March 15 (Fri) 12:45 - 13:40

Coffee Break

Coffee will be served at coffee break times in Vista Hall Lobby (B2).
Barista coffee and tea will be provided during the conference at the Grand Hall Lobby (B1) and Exhibition Hall (B3).

GENERAL INFORMATION

Internet

- + Internet lounge is located in the Exhibition Hall (B3) during the conference.
- + Wifi internet access is available at the all conference venue.

Certificate of Attendance

Participants may receive the certificate of attendance. Please contact the ICKSH 2019 Secretariat after conference via icksh@icksh.org.

Useful Phone Numbers

- + Police 112
- + Fire and Ambulance 119
- + Medical Emergency 1339

Useful Travel Website

- + Seoul City Tourism: http://www.visitseoul.net
- + Seoul Metropolitan Government: http://english.seoul.go.kr
- + Korean Tourism Organization: http://kto.visitkorea.or.kr/eng.kto

ICKSH2019 Secretariat Office

- + Onsite: Besides Cloak room, Vista Hall Lobby (B2)
- + After conference: 1F, Haeoreum Bldg., 16 Yeoksam-ro 17Gil, Gangnam-gu, Seoul, 06246, Korea
 - T. +82-2-566-6031
 - F. +82-2-566-6087
 - E. icksh@icksh.org

SPEAKER INFORMATION

Preview Room

All speakers are requested to visit the preview room no later than 2 hours before their session. They will be assisted by our staff who will help upload the presentation file to the server before the session.

LOCATION	IDA 2 (B1)		
OPERATION HOURS	March 14 (Thu) 08:00 - 18:00		
	March 15 (Fri) 08:00 - 18:00		
	March 16 (Sat) 08:00 - 12:00		

Poster Presentation

Pre-selected posters are required to have a presentation time as following schedule. After onsite reviews, the scientific committee will select Best Posters and the winners should attend the award at Closing Ceremony on March 16 (Sat).

LOCATION	Exhibition Hall (B3)
DATE & TIME	March 15 (Fri) 11:45 - 12:45



SOCIAL PROGRAM

Opening

With the opening address by Chan-Jeoung Park, Congress chairman, ICKSH 2019 will begin.

LOCATION Vista 1 (B2)

DATE & TIME March 14 (Thu) 09:00

Welcome Reception

Welcome to ICKSH 2019! The Organizing Committee will prepare welcome reception.

LOCATION Re:BAR, Vista Walkerhill Seoul (1F)

DATE & TIME March 14 (Thu) 18:30 - 20:00

Gala Dinner

Please join us to share an unforgettable evening. Enjoy the climax of ICKSH 2019 with an excellent dinner and exciting performance.

LOCATION Theater (B1)

DATE & TIME March 15 (Fri) 18:30 - 20:00

SPONSORS (Acknowledgement)







































SPONSORS (Acknowledgement)













































EXHIBITION

B1 Grand Hall Lobby




Booth No.	Grade	Company Name
G-01	Gold	Esai Korea
G-02	Gold	MSD Korea
G-03	Gold	Celltrionpharm
G-04	Gold	Yuhan Corporation
G-05	Gold	Celgene Co.
G-06	Gold	Handok
G-07	Others	ICBMT 2019
G-08	Others	IACRLRD 2019





Booth No.	Grade	Company Name
V-03	Diamond	Amgen Korea Limited
V-04	Diamond	Bristol-Myers Squibb Korea
V-05	Diamond	Takeda Pharmaceuticals
V-06	Diamond	Kyowa Kirin/Jeil Pharm
V-07	Diamond	Novartis
V-08	Diamond	Roche Korea, Co Ltd
V-01	Platinum	Janssen Korea
V-02	Platinum	Greencross Corp.

EXHIBITION



Booth No.	Grade	Company Name
P-21	Gold	Sanofi-aventis Korea Co., Ltd.
P-22	Silver	JW Pharmaceutical
P-23	Silver	MSD Korea
P-01	Bronze	Novo Nordisk Pharma Korea, Ltd.
P-02	Bronze	Korea Otsuka Pharmaceutical Co., Ltd
P-03	Bronze	Daewoong Pharmaceutical Co., Ltd
P-04	Bronze	BL&H
P-05	Bronze	Daewon Pharm
P-06	Bronze	Shire Pharma Korea
P-07	Bronze	Kwangdong



EXHIBITION

P-08	Bronze	SK Plasma
P-09 / P-10	Bronze	Pfizer Korea
P-11	Bronze	Donga ST
P-12	Bronze	TEVA-Handok
P-13	Bronze	Mundipharma Korea
P-14	Bronze	Samyang Biopharmaceuticals Corp
P-15 / P-16	Bronze	Boryung Pharmaceutical Co.,Ltd.
P-17	Bronze	Sysmex Korea
P-18	Bronze	Ono Pharma Korea
P-19	Bronze	SS Medipia
P-20	Others	Korea Marrow Donor Program

PLENARY LECTURES

MARCH 14 (Thu)



PL01-1 10:45 - 11:15 | Vista 1-3 (B2

Application of CRISPR/ Cas-9 in blood disease

Matthew H. Porteus
Stanford Medical School, Stanford University, USA



PL01-2 11:15 - 11:45 | Vista 1-3 (B2

Gene therapy for hemophilia-will there be a new era in hemophilia treatment?

Katherine Ann High

PLENARY LECTURES

MARCH 15 (Fri)



PL02-1 10:45 - 11:15 | Vista 1-3 (B2)

Breakthroughs in the treatment of aplastic anemia

Neal Stuart Young

National Institutes of Health, USA

PLENARY LECTURES

MARCH 16 (Sat)



PL03-1 10:45 - 11:15 | Vista 1-3 (B2)

The new genomics of acute lymphoblastic leukemia

Charles G. Mullighan

St. Jude Children's Research Hospital, USA



PL03-2 11:15 - 11:45 | Vista 1-3 (B2

Genetic basis and treatment of high-risk multiple myeloma

Gareth J Morgan

PRESIDENTIAL SYMPOSIUM

MARCH 14 (Thu)



PS-111:45 - 12:15 | Vista 1-3 (B2)

Stem cells in human AML

Ravi Majeti Stanford University, USA



PS-2 12:15 - 12:45 | Vista 1-3 (B2)

Precision medicine in pediatric acute lymphoblastic leukemia

Ching-Hon Pui

St. Jude Children's Research Hospital USA

DAILY PROGRAM

March 14 (Thurday)

March 15 (Friday)

March 16 (Saturday)



2019 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE & 60th ANNUAL MEETING

DAILY PROGRAM Thursday, March 14

08:00-	Registration	Lobby
09:00-	Opening Remarks	Vista 1
09:00-10:30	[JS01] KAI-KSH Joint Symposium: Immunotherapeutics in Blood Disease	Vista 1
Chairs	Tae Woo Kim (Korea University College of Medicine, Korea) Je-Jung Lee (Chonnam National University Medical School, Korea)	
JS01-1	IL-7-hyFc, a long-acting recombinant IL-7 protein, generates anti-tumor modulating both adaptive and innate immune cells in the tumor microenv Seung-Woo Lee (POSTECH, Korea)	
JS01-2	Towards next-generation CAR-T cell therapy for cancer Chan Hyuk Kim (KAIST, Korea)	
JS01-3	Immunotherapeutics in blood disease: Cytotoxic T lymphocyte therapy Hyewon Lee (National Cancer Center, Korea)	
JS01-4	Immune checkpoint inhibitor in lymphoma Yoon Seok Choi (Chungnam National University College of Medicine, Korea)	
09:00-10:30	[SS01] Bone Marrow Failure	Vista 2
Chairs	Hoon Kook (Chonnam National University Medical School, Korea) Jean Soulier (University Paris Diderot, France)	
SS01-1	Paroxysmal nocturnal hemoglobinuria in bone marrow failure Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)	
SS01-2	Germline mutations in inherited bone marrow failure Jean Soulier (University Paris Diderot, France)	
SS01-3	Telomere length and somatic mutations in aplastic anemia Dong Soon Lee (Seoul National University School of Medicine, Korea)	
10:30-10:45	Coffee Break	

DAILY PROGRAM Thursday, March 14

10:45-11:45	[PL01] Gene Therapy in Hematology	Vista 1-3
Chair	Chan-Jeoung Park (University of Ulsan College of Medicine, Korea)	
PL01-1	Application of CRISPR/Cas-9 in blood disease Matthew H. Porteus (Stanford Medical School, Stanford University, USA)	
PL01-2	Gene therapy for hemophilia-will there be a new era in hemophilia treatme Katherine Ann High (Spark Therapeutics Inc., USA)	ent?
11:45-12:45	[PS] Presidential Symposium	Vista 1-3
Chair	Bin Cho (College of Medicine, The Catholic University of Korea, Korea)	
PS-1	Stem cells in human AML Ravi Majeti (Stanford University, USA)	
PS-2	Precision medicine in pediatric acute lymphoblastic leukemia Ching-Hon Pui (St. Jude Children's Research Hospital, USA)	
12:45-13:40	[LS01] U NOVARTIS	Vista 1
Chair	Dong-Wook Kim (College of Medicine, The Catholic University of Korea, Korea)	
	Treatment free remission in CML: Promise and challenges Adam Mead (University of Oxford, UK)	
12:45-13:40	[LS02] AMGEN°	Vista 2-3
Chair	Chang-Ki Min (College of Medicine, The Catholic University of Korea, Korea)	
	Optimal treatment sequencing for patients with relapsed/refractory multiple myeloma Ajai Chari (Mount Sinai Hospital, USA)	
12:45-13:40	[LSO3] Roche	Grand Hall
Chair	Hyeon-Seok Eom (Center for Hematologic Malignancy, National Cancer Center, Kore	a)
	Current issues in the treatment of B-cell lymphoma Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)	

DAILY PROGRAM Thursday, March 14

13:40-14:40	[AS01] Lymphoid	Vista 1
Chairs	Seok Lee (College of Medicine, The Catholic University of Korea, Korea) Tran-Der Tan (Koo Foundation Sun Yat-Sen Cancer Center, Taiwan)	
AS01-1	Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia- Korean perspectives Young Rok Do (Keimyung University School of Medicine, Korea)	
AS01-2	Hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia in Taiwan – on Behalf of TSBMT Tran-Der Tan (Koo Foundation Sun Yat-Sen Cancer Center, Taiwan)	
AS01-3	Adult ALL in Malaysia Sen Mui Tan (Hospital Ampang, Malaysia)	
13:40-14:40	[AS02] Myeloid	Vista 2
Chairs	Won Sik Lee (Inje University School of Medicine, Korea) Bach Quoc Khanh (National Institute of Hematology and Blood Transfusion, Vietnam Sor Hematology and Blood Transfusion, Vietnam)	ciety of
AS02-1	CML in Philippines Priscilla B. Caguioa (University of Santo Tomas Hospital, St. Luke's Medical Center, Philipp	ines)
AS02-2	Outcome of allogeneic hematopoietic stem cell transplantation for SAA and PNH at Vietnam national institute of haematology and blood transfusion Binh Thi Thanh VO (National Institute of Hematology and Blood Transfusion, Vietnam)	
AS02-3	Hemoglobinopathy in Thailand Duantida Songdej (Ramathibodi Hospital, Mahidol University, Thailand)	
14:40-14:55	Coffee Break	
14:55-16:25	[JS02] KOGO-KSH Joint Symposium: Genomics for Precision Hematology	Vista 1
Chairs	Sanghyuk Lee (Ewha Womans University School of Medicine, Korea) Sun-Hee Kim (Sungkyunkwan University School of Medicine, Korea)	

DAILY PROGRAM Thursday, March 14

JS02-1	Understanding angioimmunoblastic T-cell lymphoma: From genomics to anin pathology Jaesang Kim (Department of Life Science, Ewha Womans University, Korea)	nal
JS02-2	Genomic pathogenesis of Epstein–Barr Virus (EBV)-induced diffuse large B cell lymphoma Sung-Yup Cho (Seoul National University College of Medicine, Korea)	
JS02-3	Current status of precision hematology Young-Uk Cho (University of Ulsan College of Medicine, Korea)	
JS02-4	Clinical application of personalized medicine for AML Joon-ho Moon (Kyungpook National University Hospital, Korea)	
14:55-16:25	[SS02] Multiple Myeloma-How is Multiple Myeloma Developed and Progressed? From 3 Different Viewpoint	Vista 2
Chairs	Chang-Ki Min (College of Medicine, The Catholic University of Korea, Korea) Yusuke Furukawa (Jichi Medical University, Japan)	
SS02-1	Immunological weapons against multiple myeloma Je-Jung Lee (Chonnam National University Medical School, Korea)	
SS02-2	Roles of bone marrow microenvironment in clonal evolution and drug resistar multiple myeloma Yusuke Furukawa (Jichi Medical University, Japan)	nce of
SS02-3	Antigen-mediated regulation in myeloma Madhav V. Dhodapkar (Emory University, USA)	
14:55-16:25	[SS03] Transplantation/Cell Therapy	Vista 3
Chairs	Hyeon-Seok Eom (Center for Hematologic Malignancy, National Cancer Center, Korea) Maria Chiara Bonini (Università Vita-Salute San Raffaele, Italy)	
SS03-1	Thymidine kinase cell therapy Maria Chiara Bonini (Università Vita-Salute San Raffaele, School of Medicine, Italy)	
SS03-2	Updates on CART cell therapy for multiple myeloma Jesús G. Berdeja (Sarah Cannon Research Institute, USA)	
SS03-3	Accelerating personalization of immune therapies for blood cancers Larry W. Kwak (City of Hope Comprehensive Cancer Center, USA)	

DAILY PROGRAM Thursday, March 14

14:55-16:25	[ES01] Iron Metabolism	Grand Hall
Chairs	Joon Seong Park (Ajou University School of Medicine, Korea) Heather Alice Leitch (University of British Columbia, Canada)	
ES01-1	Iron metabolism in hemoglobinopathies Vip Viprakasit (Medicine Siriraj Hospital, Mahidol University, Thailand)	
ES01-2	Deferasirox for iron overload patients: Preserving organ functions Norbert Gattermann (Heinrich Heine University, Düsseldorf, Germany)	
ES01-3	Management of iron overload in MDS Heather Alice Leitch (University of British Columbia, Canada)	
16:25-16:40	Break	
16:40-18:10	[SS04] Myeloproliferative Neoplasm	Vista 1
Chairs	Chul Won Choi (Korea University Guro Hospital, Korea) Robert Kralovics (CeMM Research Center for Molecular Medicine of the Austrian Sciences, Austria)	n Academy of
SS04-1	Genetic causes of myeloproliferative diseases: Stratification of patients of therapeutic targets Robert Kralovics (CeMM Research Center for Molecular Medicine of the Austrian Sciences, Austria)	
SS04-2	Molecular mechanism of MPN development by mutant calreticulin Norio Komatsu (Juntendo University School of Medicine, Japan)	
SS04-3	Interferon in myeloproliferative neoplasms Jean-Jacques Kiladjian (Saint-Louis Hospital and Paris 7 University, France)	
16:40-18:10	[SS05] Bleeding Disorder/Thrombosis	Vista 2
Chairs	Sung-Hyun Kim (Dong-A University College of Medicine, Korea) Glenn F. Pierce (World Federation of Hemophilia, USA)	
SS05-1	Progress in gene therapy for hemophilia A and B Glenn F. Pierce (World Federation of Hemophilia, USA)	

DAILY PROGRAM Thursday, March 14

5500-2	Cindy H.T. Yeung (McMaster University, Canada)	лагтасокте <i>ис</i> s ар	proacn
SS05-3	Mechanisms of cancer-associated thrombosis Nigel Mackman (University of North Carolina, USA)		
16:40-18:10	[SS06] Pediatric Disease: Inherited Hematologic Malignancies		Vista 3
Chairs	Nack Gyun Chung (College of Medicine, The Catholic Univer Lucy Ann Godley (The University of Chicago, USA)	sity of Korea, Korea)	
SS06-1	Inherited hematologic malignancies Lucy Ann Godley (The University of Chicago, USA)		
SS06-2	GATA2 deficiency: How to make the diagnosis? How to Jean Donadieu (Hopital Trousseau, France)	to treat it?	
SS06-3	Roles of monosomy 7 and SAMD9/SAMD9L mutation Hirotaka Matsui (Kumamoto University, Japan)	ns in myeloid leukem	nogenesis
16:40-18:10	[ES02] Indolent Lymphoma: From Genetics t	to the Clinic	Grand Hall
Chairs	Inho Kim (Seoul National University College of Medicine, Kor Mats Jerkeman (Lund University, Sweden)	rea)	
ES02-1	Mantle cell lymphoma -from the clinic to genetics Mats Jerkeman (Lund University, Sweden)		
ES02-2	From genetics to the clinic: Follicular lymphoma Gilles Salles (Université Claude Bernard Lyon—1 (UCBL), Fran	nce)	
ES02-3	From genetics to the clinic of chronic lymphocytic leu Wei Xu (First Affiliated Hospital of Nanjing Medical University		
18:10-18:30	Break		
18:30-20:00	Welcome Reception	Re:BAR, Vista Walker	hill Seoul (1F

09:00-10:30	[JS03] EHA-KSH Joint Symposium I: Multiple Myeloma	Vista 1
Chairs	Jae-Yong Kwak (Chonbuk National University Medical School, Korea) Francesca Maria Gay (AOU Città della Salute e della Scienza, Italy)	
JS03-1	Monoclonal antibodies in the treatment of multiple myeloma Francesca Maria Gay (AOU Città della Salute e della Scienza, Italy)	
JS03-2	Treatment for advanced multiple myeloma in Korea Chang-Ki Min (College of Medicine, The Catholic University of Korea, Korea)	
JS03-3	Experimental therapy except monoclonal antibodies Francesca Maria Gay (AOU Città della Salute e della Scienza, Italy)	
JS03-4	Clinical outcomes of cytogenetic high-risk multiple myeloma in Korea Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)	
09:00-10:30	[SS07] Benign Hematology: Hereditary Red Blood Cell Defect	Vista 2
Chairs	Jin Yeong Han (Dong-A University College of Medicine, Korea) Cornelis Leonard Harteveld (Leiden University Medical Center, The Netherlands)	
SS07-1	EuroBloodNet: The rare anaemia disorders European epidemiological platform María del Mar Mañú Pereira (University Hospital Vall d'Hebron, Vall d'Hebron Research Ins Spain)	
SS07-2	Clinical utility of high-throughput sequencing for the diagnosis of hereditary hemolytic anemia Myungshin Kim (College of Medicine, The Catholic University of Korea, Korea)	
SS07-3	The molecular spectrum of hemoglobinopathy: Thalassemia and Hb variants Cornelis Leonard Harteveld (Leiden University Medical Center, The Netherlands)	
09:00-10:30	[SS08] Histiocytosis	Vista 3
Chairs	Chuhl Joo Lyu (Yonsei University College of Medicine, Korea) Ho Joon Im (University of Ulsan College of Medicine, Korea)	
SS08-1	Langerhans cell histiocytosis 2019: New insights and opportunities Carl E. Allen (Baylor College of Medicine, USA)	
SS08-2	Treatment of hemophagocytic lymphohistiocytosis - today and tomorrow Jan-Inge Henter (Karolinska Institute, Sweden)	

SS08-3	Genetic studies on the hemophagocytic lymphohistiocytosis (HLH) in Korea Jong Jin Seo (University of Ulsan College of Medicine, Korea)	
09:00-10:30	[ES03] Acute Lymphoblastic Leukemia Gran	nd Hall
Chairs	Dae Young Zang (Hallym University College of Medicine, Korea) Chi-kong Li (The Chinese University of Hong Kong, Hong Kong)	
ES03-1	Pharmacogenetics in patients with childhood acute lymphoblastic leukemia Yoichi Tanaka (Kitasato University, Japan)	
ES03-2	Recent advances in the treatment of adult ALL Won Sik Lee (Inje University School of Medicine, Korea)	
ES03-3	Mutational landscape of ALL: Next-generation sequencing-based mutations sca strategy Seung-Tae Lee (Yonsei University College of Medicine, Korea)	inning
10:30-10:45	Coffee Break	
10:45-11:45	[PL02] Clinical Hematology	ista 1-3
Chair	Hwi-Joong Yoon (Kyung Hee University College of Medicine, Korea)	
PL02-1	Breakthroughs in the treatment of aplastic anemia Neal Stuart Young (National Institutes of Health, USA)	
11:45-12:45	[AS03] Special Report from JSH, CAH, KSH	Vista 1
Chairs	Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) Shigeru Chiba (University of Tsukuba, Japan)	
AS03-1	Developing strategies to improve efficacy and safety of chimeric antigen recept therapy Kyung-Nam Koh (University of Ulsan College of Medicine, Korea)	or cell
AS03-2	New insights into poor hematopoietic reconstitution after allo-HSCT Yuan Kong (Peking University People's Hospital, China)	
AS03-3	Targeting hotspot RHOA mutation in angioimmunoblastic T-cell lymphoma Shigeru Chiba (University of Tsukuba, Japan)	

11:45-12:45	Poster Presentation	Exhibition Hall, B3
12:45-13:40	[LS04] Bristol-Myers Squibb	Vista 1
Chair	Dong-Wook Kim (College of Medicine, The Catholic University of Korea, Kor	ea)
	Advances of CML management and the prospects for the future Susanne Saußele (University of Mannheim, Germany)	
12:45-13:40	[LS05] Takeda	Vista 2-3
Chair	Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)	
	A new paradigm shift in frontline treatment of hodgkin lymphoma Andrea Gallamini (Medical Innovation & Statistics A. Lacassagne Cancer Cer	
12:45-13:40	[LS06] KYOWA KIRIN	Grand Hall
Chair	Je-Hwan Lee (University of Ulsan College of Medicine, Korea)	
	The role of the darbepoetin alfa of the treatment for low-risk of MD Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)	S
13:40-13:50	Coffee Break	
13:50-15:05	[OP01] Acute Myeloid Leukemia/Myelodysplastic Syndrome	Vista I
Chairs	Jeong Yeal Ahn (Gachon University Gil Hospital, Korea) June-Won Cheong (Yonsei University College of Medicine, Korea)	
OP01-1	RNA sequencing as an alternative tool for detecting measurable residual disease in core binding factor acute myeloid leukemia Taehyung Kim (University of Toronto, Canada)	
OP01-2	Different predictive roles of risk group and WT1 expression in elder intensive chemotherapy or hypomethylating agent Seung-Hwan Shin (The Catholic University of Korea Yeouido St. Mary's Hosp	

0P01-3	Role of plasma gelsolin protein in the final stage of erythropoiesis and in correction myelodysplasia Eun Jung Baek (Hanyang University Guri Hospital, Korea)	of
OP01-4	Research use only and cell population data items from DxH800 analyzer is useful in discriminating MDS patients from those with cytopenia without MDS Sang Hyuk Park (University of Ulsan College of Medicine, Korea)	
OP01-5	Androgen therapy for lower-risk myelodysplastic syndrome Eun-Ji Choi (University of Ulsan College of Medicine, Korea)	
OP01-6	Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome (VIOLTET study) Hawk Kim (Gachon University Gil Medical Center, Korea)	
13:50-15:05	[OP02] Acute Lymphoblastic Leukemia Vist	:a :
Chairs	Eun Sil Park (Gyeongsang National University College of Medicine, Korea) Sung Hwa Bae (Catholic University of Daegu School of Medicine, Korea)	
0P02-1	A pragmatic, non-interventional study to evaluate effectiveness and safety of clofarabine in Korean pediatric patients with refractory or relapsed acute lymphoblastic leukemia Jung Yoon Choi (Seoul National University College of Medicine, Korea)	
OP02-2	The genotype distribution and pharmacogenetic effect on mercaptopurine dose o NUDT15 and TPMT in Korean children with acute lymphoblastic leukemia Hyery Kim (University of Ulsan College of Medicine, Korea)	f
OP02-3	Mutational profiling through exome sequencing along with MYD88 L265P analysis could facilitate the diagnosis of vitreoretinal lymphoma Borahm Kim (Yonsei University College of Medicine, Korea)	
OP02-4	Utility of MLPA as a cost effective diagnostic and prognostic method in hematologic malignancies: Experience of a tertiary care centre from India Prateek Bhatia (Post Graduate Institute of Medical Education and Research, India)	zal
OP02-5	Genetic characteristics and long-term outcomes of Korean adult patients with Ph-L ALL versus non-Ph-Like ALL Jae-Ho Yoon (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)	ike
OP02-6	Outcomes after second allogeneic hematopoietic cell transplantation in relapsed acute lymphoblastic leukemia: A single-center experience Seug Yun Yoon (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)	

13:50-15:05	[OP03] Lymphoma Vista	3
Chairs	Sung-yong Oh (Dong-A University College of Medicine, Korea) Deok Hwan Yang (Chonnam National University Medical School, Korea)	
0P03-1	Diffuse large B-cell lymphomas carrying chromosomal abnormalities showed a poor prognosis despite aggressive treatment Gi June Min (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)	
0P03-2	Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population Da Young Song (Seoul National University Hospital, Korea)	
OP03-3	International prognostic index improves prognostic value of interim PET-CT scans in diffuse large B-cell lymphoma Ho-Young Yhim (Chonbuk National University Hospital, Korea)	
0P03-4	Screening for monoclonal B-lymphocytes expansions in a hospital-based Chinese population with lymphocytosis Jiadai Xu (Zhongshan Hospital, Fudan University, China)	
OP03-5	Peripheral T cell lymphoma - Demographic profile and outcomes: 17 years experience from tertiary cancer centre, India Siva Sree Kesana (Cancer Institute (WIA), India)	
OP03-6	A multicenter retrospective analysis of clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma Jun Ho Yi (Chung-Ang University, Korea)	
13:50-15:05	[OP04] Laboratory Hematology/Cell Therapy/ Hematopoiesis Stem Cell Biology/Basic Science	all
Chairs	Myung Geun Shin (Chonnam National University Medical School, Korea) Hyun Kyung Kim (Seoul National University College of Medicine, Korea)	
OP04-1	Autophagy and unfolded protein response as the regulatory mechanism for the sensitivity of leukemia stem cells to G9a inhibitor Ji Eun Jang (Yonsei University College of Medicine, Korea)	3i-
OP04-2	3-methyladenine potentiates bortezomib-induced apoptosis of myeloma cell via increasing mitochondrial ROS through autophagy inhibition Chu Myong Seong (Ehwa Womans University Mokdong Hospital, Korea)	

OP04-3	Adoptive transfer of type 1-regulatory T cell ameliorates GVHD by partial differentiation into Foxp3+CD4+T cell with CTLA-4 and ICOS dependent manner Young-Woo Jeon (Catholic Hematology Hospital, Korea)	
OP04-4	Understanding thrombocytopenia: Role of MicroRNA in neonatal and adult megakaryopoiesis Ravi Kumar Gutti (University of Hyderabad, India)	
OP04-5	The expression level of prohibitin 2 as mitochondrial autophage receptor matches the prognostic chromosomal aberrations of hematological malignancies Jun Hyung Lee (Chonnam National University Hwasun Hospital, Korea)	
OP04-6	Epigallocatechin gallate suppresses interleukin-1 β Secretion by inhibition of NLRP3 inflammasome Cheng Zhang (Qilu Hospital, Shandong University, China)	
13:50-15:05	[OP05] Bone Marrow Failure Syndrome/Anemia/ Walker Hall 1 Cytopenia	
Chairs	Deog-Yeon Jo (Chungnam National University College of Medicine, Korea) Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea)	
OP05-1	HLA-G-ILT2 interaction contribute to suppression of marrow B-cell growth in acquired aplastic anemia Peng Chen (Qilu Hospital of Shandong University, China)	
OP05-2	A phase 3, multicenter, noninferiority study of ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors Jong Wook Lee (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)	
OP05-3	Prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria Yuzhou Huang (Peking Union Hospital, China)	
OP05-4	High prevalence of anemia in elderly in South Korea: Urgent health-care problem before post-aged society- base on data from the KNHANES Hee Won Chueh (Dong-A University College of Medicine, Korea)	
OP05-5	Vitamin-D and biochemical status in young children with beta-thalassemia major Uet Yu (Shenzhen Children's Hospital, China)	
OP05-6	Application of rapamycin up-regulating treg cell ratio in children with chronic refractory immune cytopenia - A single-center case series Hao Gu (Beijing Children Hospital, Capital Medical University, China)	

13:50-15:05	[OP06] Transplantation	Walker Hall 2
Chairs	Hyeon Jin Park (National Cancer Center, Korea) Seong Kyu Park (SoonChunHyang University College of Medicine, Korea)	
OP06-1	Predictive role of circulating immune cell subtypes early after allogeneic stem cell transplantation in patients with acute leukemia Sung-Soo Park (The Catholic University of Korea Seoul St. Mary's Hospital, Korea	
OP06-3	The outcome of hematopoietic stem cell transplantation (HSCT) in pewith hemophagocytic lymphohistiocytosis (HLH) in Korea Jun Eun Park (Ajou University School of Medicine, Korea)	diatric patients
OP06-4	HLA-haploidentical transplantation for thalassemia major using NF-08 regimen Xiaoling Zhang (Shenzhen Children's Hospital, China)	-TM haploid
OP06-5	Comparison of haploidentical and umbilical cord blood transplantatio busulfan in children and adolescent with hematologic malignancies Kyung Taek Hong (Seoul National University Hospital, Korea)	n using targeted
OP06-6	Different circulating T cells are associated with early relapse after autolopatients with multiple myeloma and classical hodgkin lymphoma Egor Batorov (Research Institute of Fundamental and Clinical Immunology, Rus	3
15:05-16:20	[OP07] Acute Myeloid Leukemia/ Myelodysplastic Syndrome	Vista 1
Chairs	Eul-Ju Seo (University of Ulsan College of Medicine, Korea) Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea)	
OP07-1	Molecular abnormalities and their correlation with the prognosis of yo patients with de novo myelodysplastic syndromes: AllMS study Rekha Chaubey (All India Institute of Medical Science, India)	ounger Indian
OP07-2	Immunogenic cell death in acute myeloid leukemia: Synergy with ven Marc Diederich (Seoul National University, Korea)	etoclax
OP07-3	Prediction of clinical outcomes with assessment of sarcopenia and adi computed tomography in adult patients with acute myeloid leukemia Jongheon Jung (National Cancer Center, Korea)	

OP07-4	Hyperleukocytosis at initial diagnosis of AML: Cytogenetic and molecular feature and prognostic implication in patients undergoing allogeneic-HSCT Silvia Park (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
OP07-5	Germline predisposition gene mutations in pediatric acute myeloid leukemia Dajeong Jeong (Seoul National University College of Medicine, Korea)
OP07-6	HSCT is an effective method to improve the prognosis of AML in children with c-Kit mutationanalysis of 131 cases Li Gao (Children's Hospital of Soochow University, China)
15:05-16:20	[OP08] Multiple Myeloma Vista 2
Chairs	Hyo Jung Kim (Hallym University College of Medicine, Korea) Sukjoong Oh (Sungkyunkwan University School of Medicine, Korea)
OP08-1	Next-generation sequencing study of $V(D)J$ rearrangements on non-CR patients showing MRD negativity by next-generation flow Naery Yang (Seoul National University College of Medicine, Korea)
OP08-2	Bone marrow tracer uptake pattern of PET/CT in multiple myeloma: Image interpretation criteria and prognostic value Jing Li (Zhongshan Hospital, Fudan University, China)
OP08-3	Real world experience of carfilzomib, and dexamethasone versus pomalido- mide-based combination chemotherapy after a 2nd-Line therapy in RRMM Ji Hyun Lee (Dong-A University Hospital, Korea)
OP08-4	PD-1 blockade reinvigorates bone marrow CD8+T cells from multiple myeloma patients in the presence of TGF-B inhibition Yoon Seok Choi (Chungnam National University College of Medicine, Korea)
OP08-5	A multicenter, phase II study of response-adapted lenalidomide-based therapy for elderly patients with newly diagnosed multiple myeloma in Korea Kwai Han Yoo (Gachon University Gil Medical Center, Korea)
OP08-6	Preclinical and clinical results of combination immunotherapy; Cancer vaccine with immune modulator, checkpoint inhibitors and epigenetic regulator

15:05-16:20	[OP09] Lymphoma/Histiocytosis	Vista 3
Chairs	Seong Hyun Jeong (Ajou University School of Medicine, Korea) Hyoung Soo Choi (Seoul National University College of Medicine, Korea)	
0P09-1	Clinical features and treatment outcomes of hodgkin lymphoma: A retrospective review in a Malaysian tertiary centre Yang Liang Boo (Hospital Sultanah Aminah, Malaysia)	
0P09-2	Primary central nervous system lymphoma : An institutional experience with uniform chemotherapy protocol Pooja Gogia (Sarvodaya Hospital and Research Centre, India)	e from India
0P09-3	Busulfan, etoposide, cytarabine and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin Jae-Cheol Jo (Ulsan University Hospital, University of Ulsan College of Medicine, Korea)	
0P09-4	Predictive parameters for neutropenia after R-CHOP chemotherapy wit peg G-CSF in patients with diffuse large B-cell lymphoma Do Young Kim (Pusan National University Hospital, Korea)	h prophylactic
OP09-5	Clinical characteristics of childhood hemophagocytic syndrome and analysis of underlying genetic deficiency Huirong Mai (Shenzhen Children's Hospital, China)	
OP09-6	Identification of genetic mutation in pediatric patients with HLH: The sclinical research network for histiocytosis Hyery Kim (University of Ulsan College of Medicine, Korea)	tudy of Korean
15:05-16:20	[OP10] Myeloproliferative Neoplasm/ Chronic Myeloid Leukemia	Grand Hal
Chairs	Ki-Seong Eom (College of Medicine, The Catholic University of Korea, Korea) Min Kyoung Kim (Yeungnam University College of Medicine, Korea)	
0P10-1	An epidemiologic study for disease transformation and second cancers patients with myeloproliferative neoplasms Junshik Hong (Seoul National University Hospital, Korea)	in Korean
OP10-2	The temporal sequence and the differences of somatic mutation acqui mines clinical behaviors of JAK2 positive myeloproliferative neoplasms as Min Brun (Sepul National University Boranga Medical Center Korea)	sition deter-

OP10-3	Retrospective screening for myeloproliferative neoplasms in patients with cerebra infarctions as revealed using the revised 2016 WHO criteria	
	Ik-Chan Song (Chungnam National University Hospital, Korea)	
OP10-4	Clinical characteristics and risk groups of chronic myeloid leukemia in children Quoc Thanh Nguyen (University of Medicine and Pharmacy, Vietnam)	
OP10-5	Expression and clinical significance of PTEN gene in chronic mye patient in Indian population Asgar Ali (All India Institute of Medical Sciences Patna, Bihar, India)	loid leukemia (CML)
OP10-6	Pilot prospective phase II study of Nilotinib combined by chemo blastic phase of chronic myeloid leukemia or bcr-Abl positive acu Hawk Kim (Gachon University Gil Medical Center, Korea)	
15:05-16:20	[OP11] Platelet/Hemostasis/Thrombosis	Walker Hall
Chairs	Sun-Young Kong (National Cancer Center, Korea) Soo-Mee Bang (Seoul National University College of Medicine, Korea)	
OP11-1	Single-center clinical data analysis of hereditary thrombocytoper	nia in children with
	chronic thrombocytopenia Jingyao Ma (Beijing Children's Hospital, Capital Medical University, Natior Health, China)	nal Center of Children's
0P11-2	Developing a diagnostic predictive model for immune thrombot based on immature platelet fraction Min Ji Jeon (Korea University Guro Hospital, Korea)	cytopenic purpura
0P11-3	Insufficient receptor editing leads to B cell central intolerance and subsequent autoartibodies accumulation in primary immune thrombocytopenia Zi Sheng (Qilu Hospital, Shandong University, China)	
0P11-4	ROTEM parameters as predicting factors for bleeding in immune	thrombocytopenic
	purpura Huu Tuan Nguyen (Cho Ray Hospital, Vietnam)	
OP11-5	Increased pathogenic Th17 cells in primary immune thrombocyt Ju Li (Qilu Hospital, Shandong University, China)	ropenia
0P11-6	Prediction value of risk assessment model deep vein thrombosis tion score	with padua predic-

Iswandi Darwis (Faculty of Medicine, Lampung University, Indonesia)

15:05-16:20	[OP12] Transplantation	Walker Hall 2
Chairs	Byung-Su Kim (Hallym University College of Medicine, Korea) Eun Sun Yoo (Ewha Womans University School of Medicine, Korea)	
0P12-1	Cytoprotective autophagy in bone marrow endothelial cells enhance he stem cells in poor graft function patients after allo-transplant Xie-Na Cao (Peking University People's Hospital, China)	ematopoietic
OP12-2	Aberrant bone marrow M1/M2 macrophage polarization may contribute to prolonged isolated thrombocytopenia after allotransplantation Hong-Yan Zhao (Peking University, China)	
0P12-3	G-CSF-induced macrophage polarization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplant Qi Wen (Peking University People's Hospital, China)	
0P12-4	Early transplantation-related mortality within 50 days after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia Seom Gim Kong (Kosin University Gospel Hospital, Korea)	
OP12-5	Incidence of anicteric veno-occlusive disease/sinusoidal obstruction syndrome and defibrotide efficacy following hematopoietic stem cell transplant Richard Martin (Jazz Pharmaceuticals, UK)	
0P12-6	Phase I trial of repeated infusions of bone-marrow derived mesenchymasteroidrefractory chronic graft-versus-host disease patients Nayoun Kim (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)	al stem cells in
16:20-16:35	Break	
16:35-18:05	[SS09] Future Information and Communications Technologies (ICT) based Medicine	Vista 1
Chairs	Dae-Young Kim (Philip Morris International, Korea) Ju Han Kim (Seoul National University College of Medicine, Korea)	
SS09-1	Deep learning for CRISPR-Cpf1 research Sungroh Yoon (Seoul National University, College of Engineering, Korea)	
SS09-2	Precision dinner: Genomes and health records Ju Han Kim (Seoul National University College of Medicine, Korea)	

SS09-3	Connected health and wellness journey Jack Ahn (Samsung Electronics, USA)	
16:35-18:05	[SS10] Acute Myeloid Leukemia/ Vis Myelodysplastic Syndromes	sta 2
Chairs	Je-Hwan Lee (University of Ulsan College of Medicine, Korea) Amer M. Zeidan (Yale University, USA)	
SS10-1	Genomics of core-binding factor AML Nicolas Duployez (Lille University Hospital, France)	
SS10-2	Precision medicine in AML in the era of novel agents Gail J. Roboz (Weill Medical College of Cornell University, USA)	
SS10-3	Incorporation of molecular assessments in risk stratification for myelodysplastic syndromes: Ready for prime time? Amer M. Zeidan (Yale University, USA)	
16:35-18:05	[SS11] Chronic Myeloid Leukemia Vis	sta 3
Chairs	Sang Kyun Sohn (Kyungpook National University School of Medicine, Korea) Simona Soverini (University of Bologna, Italy)	
SS11-1	Is chronic myeloid leukemia a single hit disorder?: Evidence from next-generation sequencing data Dennis Kim (University of Toronto, Princess Margaret Cancer Centre, Canada)	
SS11-2	NGS-based ABL1 kinase domain mutation detection Simona Soverini (University of Bologna, Italy)	
SS11-3	Precision medicine and immunity in CML Satu Mustjoki (University of Helsinki, Finland)	
16:35-18:05	[ES04] Coagulation: Global Assay of Hemostasis Grand	Hall
Chairs	Jaewoo Song (Yonsei University College of Medicine, Korea) Sung-Hyun Kim (Dong-A University College of Medicine, Korea)	
ES04-1	Early "Goal-directed Coagulation Therapy" approaches for the management of acute trauma-hemorrhage and trauma-induced coagulopathy Marc Guido Maegele (Witten/Herdecke University, Germany)	

ESU4-2	Clinical application of clot waveform analysis in hemophilia treatme Keiji Nogami (Nara Medical University, Japan)	nt
ES04-3	Thrombin generation assay Bas de Laat (Synapse Research Institute, The Netherlands)	
18:05-18:30	Break	
18:30-20:00	Gala Dinner Wa	alkerhill Theater, B1

DAILY PROGRAM Saturday, March 16

07:30-08:30	Business Meeting Walker Hall 2	
08:30-09:00	Working Party Reports Vista 1	
09:00-10:30	[JS04] EHA-KSH Joint Symposium II - Vista 1 Chronic Myelogenous Leukemia	
Chairs	Chul Won Jung (Sungkyunkwan University School of Medicine, Korea) Susanne Saußele (University of Mannheim, Germany)	
JS04-1	Europe's experience of treatment-free remission in CML Susanne Saußele (University of Mannheim, Germany)	
JS04-2	Korea's experience of treatment-free remission in CML Hawk Kim (Gachon University College of Medicine, Korea)	
JS04-3	TKI-related cardiovascular toxicities in Europe Susanne Saußele (University of Mannheim, Germany)	
JS04-4	Long-term safety of tyrosine kinase inhibitors in chronic myeloid leukemia patients Jee Hyun Kong (Yonsei University College of Medicine, Korea)	
09:00-10:30	[SS12] Childhood Acute Lymphoblastic Leukemia : Recent Updates of Prospective Trial of Pediatric ALL in Asia	
Chairs	Young Tak Lim (Pusan National University College of Medicine, Korea) Allen Yeoh Eng Juh (National University of Singapore, Singapore)	
SS12-1	Treatment of childhood ALL with IKZF1 deletion (Malaysia-Singapore ALL 2010 Study) Allen Yeoh Eng Juh (National University of Singapore, Singapore)	
SS12-2	Multicenter clinical trial of pediatric acute lymphoblastic leukemia in China: CCLG 2008 study Chi-kong Li (The Chinese University of Hong Kong, Hong Kong)	
SS12-3	Recent updates of prospective trials for ALL in Japan Yasuhiro Okamoto (Kagoshima University Graduate School of Medical and Dental Sciences, Japan)	

DAILY PROGRAM Saturday, March 16

09:00-10:30	[SS13] Lymphoma	Vista 3
Chairs	Seok-Goo Cho (College of Medicine, The Catholic University of Korea, Korea) Javeed Iqbal (University of Nebraska Medical Center, USA)	
SS13-1	Pathogenesis of EBV-associated lymphoproliferative disorders Hiroshi Kimura (Nagoya University Graduate School of Medicine, Japan)	
SS13-2	Molecular understanding of peripheral T-cell lymphoma Javeed Iqbal (University of Nebraska Medical Center, USA)	
SS13-3	Clinical application of cell-free DNA in lymphoma Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)	
09:00-10:30	[SS14] Advances in Technology	Grand Hall
Chairs	Yonggoo Kim (College of Medicine, The Catholic University of Korea, Korea) Christoph A. Merten (European Molecular Biology Laboratory (EMBL), Germany)	
SS14-1	Droplet microfluidics in antibody discovery, immune repertoire sequencir sonalized cancer therapy Christoph A. Merten (European Molecular Biology Laboratory (EMBL), Germany)	ng and per-
SS14-2	Applications of single-cell mass cytometry in hematologic malignancies Gregory Behbehani (The Ohio State University- the James Cancer Center, USA)	
SS14-3	Prediction of acute myeloid leukemia risk in healthy individuals Liran I. Shlush (Weizmann Institute of Science, Israel)	
10:30-10:45	Coffee Break	
10:45-11:45	[PL03] Genomics in Lymphoid Malignancies	Vista 1-3
Chair	Hyeoung-Joon Kim (Chonnam National University Medical School, Korea)	
PL03-1	The new genomics of acute lymphoblastic leukemia Charles G. Mullighan (St. Jude Children's Research Hospital, USA)	
PL03-2	Genetic basis and treatment of high-risk multiple myeloma Gareth J Morgan (NYU Myeloma Centre, USA)	
11:45-12:30	Award Ceremony & Closing	Vista 1-3



2019 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE & 60th ANNUAL MEETING

PP-001 Inhibition of Unc-51-Like kinase 1 (ULK1) preferentially induces apoptosis and autophagy in FLT3-ITD- mutated acute myeloid leukemia cells

<u>Ji Eun Jang</u>¹, Ju-In Eom², Hoi-Kyung Jeung², Haerim Chung¹, Yu Ri Kim¹, June-Won Cheong¹, Yoo Hong Min*¹

PP-002 RNA CRISPR-Cas9 efficiently down regulates pCrKL signalling in K562 BCR-ABL cell line: Insights from in-vitro experiments with gene editing

Prateek Bhatia*, Aditya Singh

Pediatric Hematology-Oncology Unit, Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India

PP-003 HTLV-1 bZIP factor modulates p53 pathway by stabilizing PICT1 complex

<u>Takayuki Ohshima</u>*, Rio Yamada, Risa Mukai, Kanata Yoshimoto, Yu Maruoka Faculty of Pharmaceutical Sciences at Kaqawa Campus, Tokushima Bunri University, Japan

PP-004 Prognostic impact of interim and post-treatment positron emission tomography status in mantle cell lymphoma patients treated with frontline R-CHOP

Young-Woo Jeon^{1,2,3}, Seugyun Yoon¹, Ki-Joon Min¹, Sung-Soo Park¹, Silvia Park¹, Jae-Ho Yoon¹, Sung-Eun Lee¹, Byung-Sik Cho¹, Ki-Seong Eom¹, Yoo-Jin Kim¹, Hee-Je Kim¹, Seok Lee¹, Chang-Ki Min¹, Jong Wook Lee¹, Seok-Goo Cho*^{1,2,3}

PP-005 Genetic alterations and their clinical implications in langerhans cell histiocytosis

<u>Kyung-Nam Koh</u>¹, Sung Min Chun², Jong Jae Kim², So Yoon Min¹, Jin Kyung Suh¹, Hyery Kim¹, Ho Joon Im¹, Jong Jin Seo*¹

¹ Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Korea

PP-006 Predictive role of circulating microRNA-29c-3p expression for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma

Sung-Soo Park¹, Tae Woo Kim¹, Seug Yun Yoon¹, Gi June Min¹, Silvia Park¹, Young-Woo Jeon^{1, 2}, Seung-Ah Yahng³, Seung-Hwan Shin⁴, Sung-Eun Lee^{1, 2}, Jae-Ho Yoon^{1, 2}, Byung-Sik Cho^{1, 2}, Ki-Seong Eom^{1, 2}, Yoo-Jin Kim^{1, 2}, Seok Lee^{1, 2}, Hee-Je Kim^{1, 2}, Seok-Goo Cho¹, Chang-Ki Min^{*}.

¹ Department of Internal Medicine, Yonsei University College of Medicine, Korea

² Avison Biomedical Research Center, Yonsei University College of Medicine, Korea

¹ Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Korea

² Hematology, Institute for Translational Research and Molecular Imagina, Catholic Institutes of Medical Science, Korea

³ Hematology, Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Korea

² Pathology, Asan Medical Center, University of Ulsan College of Medicine, Korea

¹ Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Korea

² Leukemia Research Institute, The Catholic University of Korea, Korea

³ Department of Hematology, Incheon St. Mary's Hospital. College of Medicine. The Catholic University of Korea, Korea

⁴ Department of Hematology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea

PP-007 Incidence, prevalence, mortality, and causes of death associated with Waldenström macroglobulinemia in Korea: A nationwide, population-based study

Seri Jeong¹, Seom Gim Kong², Da Jung Kim³, Sangjin Lee⁴, Ho Sup Lee^{*3}

¹ Laboratory Medicine, Kosin University College of Medicine, Korea

PP-008 Nationwide epidemiologic study for disease transformation and secondary cancers in Korean children and young adults with myeloproliferative neoplasms

Hyoung Soo Choi¹, Junshik Hong², Ju Hyun Lee³, Soo Mee Bang*³

PP-009 Distribution chemotherapy response modulating genetic polymorphisms in Armenian population

Yervand Hakobyan, Arsen Arakelyan*

Adults' Department, Hematology Center after Prof. Yeolyan MH RA, Armenia

Institute of Molecular Biology NAS RA, Armenia

PP-010 Twenty years' experiences of exchange transfusion in Korea

Min-Sun Kim, Dae-Hyun Ko*, Sang-Hyun Hwang, Heung-Bum Oh

Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Korea

PP-011 Antileukemic activity of Thiazole-Pyrazole conjugates against human leukemic cell via inhibition of epidermal growth factor receptor (EGFR)

Udaya Pratap Singh*1, Hans Raj Bhat2

¹ Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, India

PP-012 2-Phenylpyrimidine coumarin induces apoptosis via activation of caspase and inhibition of PI3K/Akt/mTOR-Kinase in human leukemic cell

S. Sinah

Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, India

PP-013 Impact of the immuno-microenvironmental changes in AML by blocking both CXCR4 and dual immune checkpoints

Hee-Sun Hwang¹, A-Reum Han¹, Ji Yoon Lee¹, Hee-Je Kim*^{1,2}

² Pediatrics, Kosin University College of Medicine, Korea

³ Hematology-Oncology, Kosin University College of Medicine, Korea

⁴ Statistics, Pusan National University, Korea

Pediatrics, Seoul National University Bundana Hospital, Korea

² Internal Medicine, Seoul National University Hospital, Korea

³ Internal Medicine, Seoul National University Bundang Hospital, Korea

² Department of Pharmaceutical Sciences, Dibrugarh University, India

¹ Leukemia Research Institute, The Catholic University of Korea Seoul St. Mary's Hospital, Korea

² Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Korea

PP-014 A case of jumping translocation of 1q42 in acute myeloid leukemia patient

<u>Cheongang Park</u>, Seon-Ho Mun, A-Jin Lee, Chang-Ho Jeon, Hun Suk Suh, Sang-Gyung Kim* *Laboratory Medicine, Daegu Catholic University Medical Center, Korea*

PP-015 Flow cytometric characteristics of distinct population in acute basophilic leukemia

<u>Seon-Ho Mun</u>, Sang-Gyung Kim*, A-Jin Lee, Hun Suk Suh, Chang-Ho Jeon, Cheongang Park Laboratory Medicine, Daeau Catholic University Medical Center, Korea

PP-016 PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis

Min Jeong Ryu^{1,2}, Jeongsu Han^{1,2,4}, Soo Jeong Kim^{1,4}, Min Joung Lee^{1,3,4}, Xianshu Ju^{1,3,4}, Yu Lim Lee^{1,3,4}, Jeong Hwan Son³, Jianchen Cui^{1,3,4}, Yunseon Jang^{1,3,4}, Woosuk Chung^{5,6}, Ik-Chan Song⁷, Gi Ryang Kweon^{1,2,4}, Jun Young Heo*^{1,3,4,5}

PP-017 A genome-wide CRISPR screen identifies PTEN critical for NL101 sensitivity in acute myeloid leukemia

Liming Lin, Shu Li, Feiqiong Gao, Jiawei Zhang, Yang Xu*

Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, China

PP-018 Efficacy and safety of lenalidomide as monotherapy and multitherapy in the management of acute myeloid leukemia: A meta-analysis

Md Sarfaraj Hussain*1, Abul Kalam Najmi2

PP-019 Decitabine efficacy and safety in the management of acute myeloid leukemia: A meta analysis of observational studies

Md Salman Hussain*1, Abul Kalam Najmi2

PP-020 Acute promyelocytic leukemia - retrospective analysis from a tertiary care oncology centre from South India

Perraju Bhaskar Bhuvan Lagudu¹, Venkatraman Radhakrishnan*¹, Prashanth Ganesan², Ganesan T S¹, Manikandan Dhanushkodi¹, Nikita Mehra¹, Jayachandran Perumal¹, Kripa Sankar¹, Gnana Sagar Tenali¹, Krishna Rathinam¹

¹ Department of Biochemistry, Chungnam National University School of Medicine, Korea

² Research Institute for Medical Science, Chungnam National University School of Medicine, Korea

³ Department of Medical Science, Chungnam National University School of Medicine, Korea

⁴ Infection Control Convergence Research Center, Chungnam National University School of Medicine, Korea

⁵ Brain Research Institute, Chungnam National University School of Medicine, Korea

⁶ Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Korea

⁷ Department of Internal Medicine, Chungnam National University Hospital, Korea

¹ Department of Pharmacognosy, Integral University, India

² Department of Pharmacology, Jamia Hamdard, India

¹ Department of Pharmaceutical Medicine, Jamia Hamdard, India

² Department of Pharmacology, Jamia Hamdard, India

¹ Medical Oncology, Cancer Institute (WIA), India

² Medical Oncology, JIPMER, India

PP-021 Impact of treatment and transplantation on survival in a phase 3 study of CPX-351 vs 7+3 in older adults with newly diagnosed, high-risk/secondary AML

Tara L. Lin¹, Jorge E. Cortes², Laura F. Newell³, Donna Hogge⁴ Richard M. Stone⁵, Jonathan E. E. Kolitz6, Gary J. Schiller⁷, Matthew J. Wieduwilt⁸, Daniel H. Ryan⁹, <u>Richard Martin*</u>¹⁰, Robert J. Ryan¹¹, Michael Chiarella¹¹, Arthur C. Louie¹¹

PP-022 CPX-351 Vs 7+3 in older adults with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) enrolled in a phase 3 study

Daniel H. Ryan¹, Jorge E. Cortes², Laura F. Newell³, Robert K. Stuart⁴, Donna Hogge⁵, Jonathan E. Kolitz⁶, Gary J. Schiller⁷, Matthew J. Wieduwilt⁸, <u>Richard Martin⁸</u>9, Robert J. Ryan¹⁰, Arthur C. Louie¹⁰

PP-023 Genetic mutation profiling of acute myeloid leukemia using targeted next generation sequencing

Ha Jin Lim¹, Jun Hyung Lee¹, Seung Yeob Lee¹, Sejong Chun¹, Seung-Jung Kee¹, Soo-Hyun Kim¹, Jong-Hee Shin¹, Seo-Yeon Ahn², Hyeoung-Joon Kim², Myung-Geun Shin^{*}1,³

¹ Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Korea

² Department of Hematology-Oncology, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Korea

¹University of Kansas Medical Center, Kansas City, KS, USA

²The University of Texas MD Anderson Cancer Center, Houston, TX, USA

³Oregon Health & Science University, Portland, OR, USA

⁴Leukemia/BMT Program of British Columbia, Vancouver, BC, Canada

⁵Dana-Farber Cancer Institute, Boston, MA, USA

⁶ Monter Cancer Center, Northwell Health System, Lake Success, NY, USA

⁷ David Geffen School of Medicine/UCLA, Los Angeles, CA, USA

⁸ University of California – San Diego Moores Cancer Center, La Jolla, CA, USA

⁹ University of Rochester, Rochester, NY, Canada

¹⁰ Jazz Pharmaceuticals, Oxford, UK

¹¹ Jazz Pharmaceuticals, Palo Alto, CA, USA

¹University of Rochester, Rochester, NY, USA

²The University of Texas MD Anderson Cancer Center, Houston, TX, USA

³Oregon Health & Science University, Portland, OR, USA

⁴ Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA

⁵Leukemia/BMT Program of British Columbia, Vancouver, BC, Canada

⁶ Monter Cancer Center, Northwell Health System, Lake Success, NY, USA

⁷ David Geffen School of Medicine/UCLA, Los Angeles, CA, USA

⁸ University of California – San Diego Moores Cancer Center, La Jolla, CA, USA

⁹ Jazz Pharmaceuticals, Oxford, USA

¹⁰ Jazz Pharmaceuticals, Palo Alto, CA, Canada

³ Brain Korea 21 Project, Center for Biomedical Human Resources, Chonnam National University, Gwangju, Korea

PP-024 Beyond hypomethylating agent (HMA) failure in elderly acute myeloid leukemia (AML) patients

Silvia Park¹, Hee-Je Kim*¹, Dong-Wook Kim¹, Yoo-Jin Kim¹, Jong Wook Lee¹, Seok Lee¹, Ki-Seong Eom¹, Seok-Goo Cho¹, Chang-Ki Min¹, Byung Sik Cho¹, Jae-Ho Yoon¹, Young-Woo Jeon¹, Sung-Soo Park¹, Gi June Min¹, Seug Yun Yoon¹, Seung-Hwan Shin², Sung-Eun Lee¹, Seung-Ah Yahng³

Department of Medicine, Seoul St. Mary's Hematology Hospital, The Catholic University of Korea, Seoul, Korea

PP-025 Dialkyl resorcinol stemphol disrupts calcium homeostasis triggering immunogenic necroptosis in acute myeloid leukemia

Jin-Young Lee, Marc Diederich*

Department of Pharmacy, College of Pharmacy, Seoul National University, Korea

PP-026 Evaluation of the ion torrent oncomineTM myeloid research assay for clinical applications in hematologic malignancy

<u>Jae Won Yun</u>¹, Heyjin Kim¹,², Jung Yoon¹, Jong Eun Park¹, Hee-Jin Kim¹, Sun-Hee Kim¹, Jong Won Kim*¹ Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of

PP-027 Role of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with NPM1wt and FLT3-ITD negative group

Ju-Hyung Kim^{1,2}, Jungmin Lee^{1,2}, Ji-Yeon Ham^{2,3}, Jang Soo Suh^{2,3}, Joon-Ho Moon*^{1,2}, Sang Kyun Sohn^{1,2}

PP-028 Gene amplification and chromothripsis in acute myeloid leukemia with complex chromosomal abnormalities

Chang Ahn Seol¹, Chan-Jeoung Park¹, Seongsoo Jang¹, Young-Uk Cho¹, Jung-Hee Lee², Je-Hwan Lee², Kyoo-Hyung Lee², Jin-Ok Lee³, Eul-Ju Seo*¹

¹ Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Korea

PP-030 Clinical application of next-generation sequencing in diagnostic work-up of patients with acute myeloid leukemia and myelodysplastic syndrome

Min Young Lee^{1,2}, Young-Uk Cho*¹, Chan-Jeoung Park¹, Seongsoo Jang¹, Ari Ahn¹

² Department of Medicine, Yeouido St. Mary's Hospital, Korea

³ Department of Medicine, Incheon St. Mary's Hospital, Korea

² Department of Laboratory Medicine, Myongji Hospital, Hanyang University Medical Center, Korea

Hematology/Oncology, Kyungpook National University Hospital, Korea

² School of Medicine, Kyungpook National University, Korea

³ Laboratory Medicine, Kyungpook National University Hospital, Korea

² Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Korea

³ Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Korea

Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Korea

² Department of Laboratory Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Korea

PP-031 Reclassifying acute myeloid leukemia according to the revised 2016 WHO classification in a large patient group

Min-Young Lee, Young-Uk Cho*, Seongsoo Jang, Eul-Ju Seo, Chan-Jeoung Park Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center, Korea

PP-032 Predictive role of geriatric assessment for early events in elderly AML fit for intensive chemotherapy; Interim data of a prospective cohort study

Gi June Min¹, Byung Sik Cho*¹, Seug Yun Yoon¹, Silvia Park¹, Seung-Ah Yahng², Young-Woo Jeon¹, Seung-Hwan Shin³, Jae-Ho Yoon¹, Sung-Eun Lee¹, Ki-Seong Eom¹, Yoo-Jin Kim¹, Seok Lee¹, Heeje Kim¹, Chang-Ki Min¹, Seok-Goo Cho¹, Dong-Wook Kim¹, Jong Wook Lee¹

PP-033 Stable disease has survival benefit after hypomethylating agent in myelodysplastic syndrome Hawk Kim*¹, Jae Sook Ahn², Young-Rok Do³, Ho Jin Shin⁴, Won Sik Lee⁵, Sung-Nam Lim⁶, Joon Ho Moon⁷, Ho Sup Lee⁸, Sung Hwa Bae⁹, Yunsuk Choi¹⁰

PP-034 Red blood cell and platelet indices: Could it predict survival of patients with myelodysplastic syndrome?

Jieun Uhm*¹, Moo-Kon Song², Young Woong Won³, Byeong Bae Park¹, Jung Hye Choi³, Young Yiul Lee¹ ¹ Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Korea

² Department of Hematology-Oncology, Hanyang University Hanmaeum Changwon Hospital, Hanyang University College of Medicine, Changwon, Korea

³ Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea

PP-035 Monocyte subset for the screening of chronic myelomonocytic leukemia

Sang Mee Hwang*, Jun Park, Seung-Ah Jeon Laboratory Medicine, Seoul National University Bundana Hospital, Korea

¹ Department of Hematology, Seoul St. Mary's Hematology Hospital, Korea

² Department of Hematology, Incheon St Mary's Hospital, Korea

³ Department of Hematology, Yeouido St. Mary's Hospital, Korea

¹ Division of Hematology, Gachon University Gil Medical Center, Gachon University College of Medicine, Korea

² Division of Hematology-Oncology, Chonnam National University Hwasun Hospital, Korea

³ Division of HematoOncology, Keimyung University Dongsan Medical Center, Korea

⁴ Division of Hematology-Oncology, Pusan National University Hospital, Korea

⁵ Division of Hematology-Oncology, Inje University Busan Baik Hospital, Korea

⁶ Division of Hematology-Oncology, Inje University Haeundae Baik Hospital, Korea

⁷ Department of Hematology/Oncology, Kyungpook National University Hospital, Korea

⁸ Division of Hematology-Oncology, Kosin University Gosper Hospital, Korea

⁹ Division of Hematology/Oncology, Daegu Catholic University Medical Center, Korea

¹⁰ Division of Hematology and Cellular Therapy, Ulsan University Hospital, University of Ulsan College of Medicine, Korea

PP-036 Polymorphism of TPMT and ITPA and their adverse effects of chemotherapy for acute lymphoblastic leukemia children in Bangladesh

<u>Sanjana Zaman</u>*^{1,2} Hiroko Fukushima³, Ryoko Suzuki³, Shoji Yoshimatsu^{3,4}, Mohammad Delwer Hossain Hawlader¹, Nobutaka Kiyokawa⁵, Takashi Fukushima²

¹ Department of Public Health, School of Health and Life Sciences, North South University, Bangladesh

² Department of Child Health, Graduate School of Comprehensive Human Sciences Majors of Medical Sciences, University of Tsukuba, Japan

³ Department of Child Health, Faculty of Medicine, University of Tsukuba, Japan

⁴ Department of Epidemiology and Clinical Research, Research Institute of Tuberculosis, Tokyo, Japan

⁵ Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan

PP-037 Customised superparamagnetic iron-oxide polymeric nanocarriers for targeted and controlled delivery of anti-tumor drug in acute lymphoblastic leukemia

Anas Ahmad

Nano-Therapeutics, Institute of Nano Science and Technology (INST), India

PP-038 Immuno phenotypes and the value of cluster of differentation in acute leukemia at National Children's Hospital, Vietnam

Thi Ha Dang¹, Thanh Binh Nguyen*², Thi Nghiem Luong¹, Thi Duyen Nguyen¹, Hong Ha Tran Thi¹, Thi Thoa Ta¹, Thu Giang Phan²

¹ Hematology Laboratory Department, National Children's Hospital, Vietnam

² Faculty of Immunology, Hanoi Medical University, Vietnam

PP-039 Temporal trends in nutritional status of children with acute lymphoblastic leukemia during intensive phase of treatment

Venkatraman Radhakrishnan

Medical Oncology, Cancer Institute, Chennai, India

PP-040 Preliminary experience at a single centre in India with a collaborative multicentre risk stratified and response adapted protocol for treating pediatric ALL

Venkatraman Radhakrishnan

Medical Oncology, Cancer Institute, Chennai, India

PP-041 Homozygous TCF3 mutation is associated with severe hypogammaglobulinemia and acute lymphoblastic leukemia

Ridha Barbouche*1, Lamia Aissaoui2, Yu-Lung Lau3, Meriem Ben-Ali1

¹ Immunology, Pasteur Institute of Tunis, Tunis, Tunisia

² Hematology, Aziza Othmana Hospital, Tunis, Tunisia

³ Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong

PP-042 A comparative study of palmar and digital dermatoglyphic patterns among leukemic patients & non-leukemic Individuals: A meta-analysis

Ameet Kumar Jha*1, Sujatha D'costa2

¹ Preclinical Sciences, Texila American University, Guyana

PP-043 The effect of GATA3 rs3824662 gene polymorphism on children with pre-B-cell acute lymphoblastic leukemia treated by CCLG-ALL 2008 protocol

Xinran Chu¹, Dong Wu², Jing Gao¹, Shaoyan Hu*¹

PP-044 Comparision of parental perception on "Health Related Quality of Life (hrgol)" in children with acute lymphoblastic leukemia (on treatment) and normal

Aisha Mahesar*, Mansoor Mazari, Usman Waheed

Department of Haematology/Oncology, Children's Hospital Lahore, Pakistan

PP-045 Detecting diplotype of NUDT15 variants and 6-Mercaptopurine sensitivity by target sequence cDNA of NUDT15

Der-Shiun Wang^{1,2,3}, Chih-Hsiang Yu^{3,4}, Dong-Tsamn Lin^{3,6,7}, Shiann-Tarng Jou^{3,6}, Meng-Yao Lu^{3,6}, Hsiu-Hao Chang^{3,6}, Shu-Wha Lin^{4,7}, Hsuan-Yu Chen⁵, Yung-Li Yang^{*3,6,7}

PP-046 Sociodemographic, clinical and laboratory profile of acute leukemia patient in Sanglah General Hospital, Bali

Ni Putu Windi Sukma Putri*, Geitha Puspita Darmi, Ni Made Renny Anggreni Rena

Undergraduate Program, Faculty of Medicine, Udayana University, Indonesia

Hematology and Medical Oncology Division. Internal Medicine Department, Faculty of Medicine, Udayana University, Indonesia

Two cases of burkitt leukemia with IGH-MYC rearrangement associated with precursor B-cell PP-047 phenotype

<u>Jung Yoon</u>¹, Jae Won Yun¹, Keon Hee Yoo², Chul Won Jung³, Sun-Hee Kim¹, Hee-Jin Kim*¹

² Anatomy, American University of Antiqua, Antiqua&Barbuda

¹ Department of Hematology and Oncology, Children's Hospital of Soochow University, China

² Department of Pediatric, Qiyuan People's Hospital, China

¹ Department of Pediatric, Tri-Service General Hospital, Taiwan

² Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taiwan

³ Department of Pediatrics, National Taiwan University Hospital, Taiwan

⁴ Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taiwan

⁵ Institute of Statistical Science, Academia Sinica, Taiwan

⁶ Department of Pediatrics, College of Medicine, National Taiwan University, Taiwan

⁷ Department of Laboratory Medicine, National Taiwan University Hospital, Taiwan

Department of Laboratory Medicine & Genetics, Sungkyunkwan University School of Medicine, Korea

² Pediatrics, Sungkyunkwan University School of Medicine, Korea

³ Internal Medicine, Sungkyunkwan University School of Medicine, Korea

PP-048 Chymeric antigen receptor (CAR) T-cell immunotherapy: A new promising therapy for patients with relapsed B-cell acute lymphoblastic leukemia

Indah Sagitaisna Putri*, Bastomy Eka Rezkita, Fairuz Zahidah Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia

PP-049 Anti-leukemic effect of ajwain oil against DMBA induced leukemic rat model: Possible mechanism of action

Vikas Kumar*1, Firoz Anwar2

¹ Pharmaceutical Sciences, SHUATS, India

² Biochemistry, Kingabdulaziz University, Saudi Arabia

PP-050 Chemo-protective effect of lemon oil against the benzene induced leukemia via regulation of growth factors and inflammatory mediators

Deeksha Chauhan*1, Prakash Bhatt2, V Kumar3

¹ Applied, University of Allahabad, India

² Pharmacy, Jamia Hamdard, India

³ Drug Discovery Laboratory, Shalom Institute of Health and Allied Sciences, India

PP-051 Detection of complex variant t(9;22) chromosome translocations in newly diagnosed cases of chronic myeloid leukaemia. A single institute experience

Noorulain Fareed*, Noor Muhammad Somroo, M. Saeed Quraishy, Sana Rafiq Oncology/ Hematology, Dr. Ruth K. M. Pfau, Civil Hospital, Karachi, Pakistan

PP-052 Optimal time points for BCR-ABL1 tyrosine kinase domain mutation analysis based on European LeukemiaNet recommendations in chronic myeloid leukemia

Hea-Lyun Yoo¹, Soo-Hyun Kim¹, Soo-Young Choi¹, Mi-Young Lee¹, Hye-Young Song¹, Ki-Hoon Kang¹,

Kyoung-Mi Ki¹, Ji-Hyung Suh¹, Sun-Young Yang¹, Dong-Wook Kim*^{1,2}

¹ Leukemia Research Institute, The Catholic University of Korea, Korea

² Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Korea

PP-053 A retrospective study of paediatric chronic myeloid leukemia from a tertiary cancer centre, India

Siva Sree Kesana¹, Venkatraman Radhakrishnan*¹, Prasanth Ganesan², Sagar Tenali¹

¹ Medical Oncology, Cancer Institute(W.I.A), India

² Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, India

PP-054 Population pharmacokinetic and dose-response analyses of dasatinib to support dosage in Asian pediatric patients with chronic myeloid leukemia

Sai Bathena¹, Amit Roy¹, Takafumi Ide*²

¹ Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, USA

² Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb K.K., Japan

PP-055 A study of treatment-free remission evaluation in real-world chronic myeloid leukemia; Estimated cost-effectiveness analysis (ASTER-C)

Bora Nam¹, Soktae Kim¹, Jae Hoon Lee², Kwai Han Yoo², Hawk Kim*²

¹ Department of International Trade, Dongkuk University, Korea

² Division of Hematology, Gachon University Gil Medical Center, Gachon University College of Medicine, Korea

PP-056 Highly sensitive detection of BCR-ABL in clinical samples by QXDx BCR-ABL %IS digital droplet PCR

<u>Hee-Jung Chung</u>, Mina Hur*, Hannah Kim, Sumi Yoon, Hee-Won Moon, Yeo-Min Yun Laboratory Medicine, Konkuk University Medical Center, Korea

PP-057 Survival outcomes with addition of methotrexate and cytarabine onto standard treatment for diffused large B-cell lymphoma (DLBCL): 3-Year follow-up

<u>Chee Chean Dang</u>*¹, Yong Khee Guan², Kuo Zang Wong¹, Hsieng Yew Kuan¹, Mohd Firdaus Lazim¹, Chiet Yin Yau¹

PP-058 High serum glucose during chemotherapy is associated with inferior survival outcome in patients with non-Hodgkin lymphoma

<u>Jihyun Kwon</u>*, Eu Jeong Ku

Internal Medicine, Chunbuk National University Hospital, Korea

PP-059 Follicular lymphoma with leukemic presentation

Shih-Sung Chuang*¹, Shang-Wen Chen², Yen-Chuan Hsieh¹, Chun-Chi Kuo¹, Hung-Chang Wu³, Yin-Hsun Feng³ ¹ Patholoov, Chi-Mei Medical Center, Taiwan

PP-060 Milk- alkali syndrome with pulmonary calcification in diffused large B cell lymphoma: A case report

Lien Nhi Tran Thi

Oncology, Vietnam National Children's Hospital, Vietnam

PP-061 Asian variant of intravascular large B-cell lymphoma

Sang Eun Yoon*¹, Junhun Cho², Duck Cho³, Hee-Jin Kim³, Sun-Hee Kim³, Young Hyeh Ko², Won Seog Kim¹, And Seok Jin Kim^{1,4}

¹ Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center,

Sungkyunkwan University School of Medicine, Seoul, Korea

² Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine. Seoul. Korea

³ Department of Laboratory Medicine & Genetics, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea

Sungkyunkwan University, Seoul, Korea

¹ Pharmacy (Hematology), Hospital Melaka, Malaysia

² Medicine (Hematology), Pantai Hospital Ayer Keroh, Malaysia

² Hemato-Oncology, Lioying Chi-Mei Hospital, Taiwan

³ Hemato-Oncoloav, Chi-Mei Medical Center, Taiwan

⁴Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology,

PP-062 Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma

Gyeong-Won Lee*1, Se-II Go2, Sungwoo Park1, Myoung Hee Kang2, Hoon-Gu Kim2

¹ Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Korea

² Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Korea

PP-063 Clinical characteristics and outcome of acquired immune deficiency syndrome (AIDS) related lymphomas (ARL) in hospital Ampang

<u>Christopher, Chin Keong Liam</u>*¹, Sen Mui Tan¹, Jerome, Tsen Chuen Tan¹, Tee Chuan Ong¹, Jameela Sathar¹, Suraya Hanim Abdullah Hashim², Yi Lin Lee³, Kian Boon Law³

PP-064 Necropotosis was restored in chronic lymphocytic leukemia by inhibiting LTB-NF-KB-LEF1 pathway

Yifeng Sun, Jing Li, Zhao Xu, Jiadai Xu, Peng Liu*

Department of Hematology, Zhongshan Hospital, Fudan University, China

PP-065 Prevalence and immunophenotypic characteristics of monoclonal B-cell lymphocytosis in Korea

In Young Yoo¹, Sung Hoan Bang¹, Seok Jin Kim², Hee Jin Kim¹, Sun-Hee Kim¹, Duck Cho*¹

PP-066 Event free survival at 24 months is a surrogate end point for subsequent overall survival in peripheral T-cell lymphoma

Yu Ri Kim¹, Soo-Jeong Kim², June-Won Cheong², Haerim Chung², Ji Eun Jang², Yundeok Kim¹, Yoo Hong Min². Jin Seok Kim⁸

¹ Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Korea

PP-067 Prurigo nodularis and hodgkin's Lymphoma – A rare association

Zher Lin Go*1, Qin Jian Low2, Nurul Aisyah Abd Rahman1, Ling Fong Ng1, Ngee Siang Lau3

PP-068 The protection effect of moringa extract from lymphoma cell metastasis through decreasing ICAM-1 in Internal carotid artery of metabolic syndrome rats

Mohamad Arif Fikri*, Bastomy Eka Rezkita, Rani Luthfiany Putri, Dyah Ratna

Pathology Anatomy, Sebelas Maret University, Indonesia

¹ Hematology, Hospital Ampang, Malaysia

² Infectious Disease, Hospital Ampang, Malaysia

³ Clinical Research Ward, Hospital Ampang, Malaysia

¹ Department of Laboratory Medicine and Genetics, Samsung Medical Center, Korea

² Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Korea

² Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Korea

¹ Department of Internal Medicine, Hospital Melaka, Malacca, Malaysia

² Department of Internal Medicine, Hospital Sultanah Nora Ismail Batu Pahat, Johore, Malaysia

³ Department of Hematology, Hospital Ampang, Selangor, Malaysia

PP-069 Ibrutinib vs real-world (RW) treatment outcomes in chronic lymphocytic leukemia by Del11q status: Adjusted comparison of clinical trial and RW data

<u>Gilles Salles</u>*¹, Evelyne Callet-Bauchu², Hervé Besson³, Margaret Doyle⁴, Jamie Garside⁵, Martin Spacek⁶, Michael Doubek^{7,8}

¹ Hematology Department, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard, Pierre Bénite, France

² Laboratoire d'He 'matologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard, Pierre Bénite, France

³ Statistics & Modellina, Janssen EU HEMAR, Belaium

⁴ Medical Affairs, Janssen-Cilag EMEA, Ireland

⁵ HEMAR, Janssen EMEA, United Kingdom

⁶ Department of Oncology, General Faculty Hospital Prague, France

⁷ Department of Internal Medicine – Hematology and Oncology, University Hospital and Faculty of Medicine, France

⁸ CEITEC, Masaryk University, Belgium

PP-070 A case of EBV-Positive NK/T cell lymphoma progressed from severe mosquito bite allergy

<u>Seunghoo Lee</u>¹, Chan-Jeoung Park*¹, Young-Uk Cho¹, Sang-Hyun Hwang¹, Seongsoo Jang¹, Jooryung Huh², Hyery Kim³

¹ Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Korea

² Pathology, University of Ulsan College of Medicine and Asan Medical Center, Korea

³ Pediatrics, University of Ulsan College of Medicine and Asan Medical Center, Korea

PP-071 Efficacy of Ibrutinib-Rituximab versus Real-World (RW) regimens for waldenström's macroglobulinemia: Adjusted comparison of clinical trial and RW data

Gilles Salles*¹, Lionel Karlin¹, Hervé Besson², Christoph Tapprich³, Jamie Garside⁴

Centre Hospitalier Lyon-Sud. Hospices Civils de Lyon, Université Claude Bernard. Pierre Bénite, France

² Janssen EU HEMAR Statistics & Modelling, Beerse, Belgium

³ Janssen-Cilag GmbH, Neuss, Germany

⁴ Janssen EMEA HEMAR, Hiah Wycombe, UK

PP-072 Treatment outcomes of adult primary mediastinal B-cell lymphoma (PMBCL) treated with dose-adjusted R-EPOCH as frontline therapy in tertiary hospital

Chee Chean Dang*1, Zher Lin Go2, Ngee Siang Lau2

¹ Department of Pharmacy (Haematology/Oncology) Malaysia, Hospital Melaka, Malaysia

² Department of Medicine (Haematology), Hospital Melaka, Malaysia

PP-073 Triple improvement in the clinical, laboratory, and radiologic manifestations of multicentric castleman disease after treatment with siltuximab

<u>Gi June Min</u>¹, Seok-Goo Cho*¹, Seug Yun Yoon¹, Silvia Park¹, Seung-Ah Yahng², Seung-Hwan Shin³, Jae-Ho Yoon¹, Sung-Eun Lee¹, Byung Sik Cho¹, Ki-Seong Eom¹, Yoo-Jin Kim¹, Seok Lee¹, Hee-Je Kim¹, Chang-Ki Min¹, Dong-Wook Kim¹, Jong Wook Lee¹

¹ Department of Hematology, Seoul St. Mary's Hematology Hospital, Korea

² Department of Hematology, Incheon St Mary's Hospital, Korea

³ Department of Hematology, Yeouido St. Mary's Hematology Hospital, Korea

PP-074 A 15-year-old male diagnosed with mantle cell lymphoma, presenting with mediastinal mass Jae Min Lee * 1, Mi Jin Gu²

¹ Department of Pediatrics, College of Medicine, Yeungnam University, Korea

PP-075 Treatment abandonment amongst patients with hematological malignancy in TYA age group Taha Sethiiwala*, Venkatraman Radhakrishnan

Department of Medical Oncology, Cancer Institute Adyar, Chennai, India

PP-076 Effect of the dose of rituximab on survival outcomes of the DLBCL treated with rituximab-CHOP; Based on the national health information database

<u>Jung Yeon Lee¹</u>, Hye Sim Kim², Shin Young Hyun¹, Seung Taek Lim¹, Kwang Yong Shim¹, Jong In Lee¹, Jee Hyun Kong*¹

PP-077 Clinical impact of ibrutinib in refractory or relapsed mantle cell lymphoma: Single-Center experience in clinical practice

<u>Young-Woo Jeon</u>^{1,2,3}, Seugyun Yoon¹, Ki-Joon Min¹, Sung-Soo Park¹, Silvia Park¹, Jae-Ho Yoon¹, Sung-Eun Lee¹, Byung-Sik Cho¹, Ki-Seong Eom¹, Yoo-Jin Kim¹, Hee-Je Kim¹, Seok Lee¹, Chang-Ki Min¹, Jong Wook Lee¹, Seok-Goo Cho*^{1,2,3}

PP-078 Results and prospects for the treatment of anaplastic cell lymphoma in adult patients Saidrakhim Nodirovich

Hematology, Tashkent Medical Academy, Uzbekistan

PP-079 Genetic and non-genetic risk factors of bleomycin-Induced pulmonary toxicity in south indian patients with hoddkin lymphoma

<u>Dimpal Thakkar</u>*¹, Sandhiya Selvarajan², Biswajit Dubashi³

PP-080 A rare case of high grade nodal marginal zone B cell lymphoma with diffuse bone marrow involvement and igm-type monoclonal paraproteinemia

<u>Sang Hyuk Park</u>¹, Jaewook Kim¹, Joseph Jeong¹, Seon-Ho Lee¹, Hee Jeong Cha², Seol Hoon Park³, Yunsuk Choi⁴, Jae-Cheol Jo⁴, Ji-Hun Lim^{*1}

² Department of Pathology, College of Medicine, Yeungnam University, Korea

¹ Internal Medicine, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Korea

² Center of Biomedical Data Science, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Korea

¹ Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Korea

² Hematology, Institute for Translational Research and Molecular Imaging, Catholic Institutes of Medical Science, Korea

³ Hematology, Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Korea

¹ Pharmacology, JIPMER, India

² Clinical Pharmacology, JIPMER, India

³ Medical Oncology, JIPMER, India

Department of Laboratory Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea

² Department of Pathology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea

³ Department of Nuclear Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea

⁴ Department of Hematology and Cellular Therapy, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea

PP-081 9-year-old boy diagnosed with X-linked lymphoproliferative disease type 1 - Case report

<u>Jae Min Lee</u>*¹, Hyery Kim², Ja Young Seo³, Jong Jin Seo²

¹ Department of Pediatrics, College of Medicine, Yeungnam University, Korea

² Department of Pediatrics, Asan Medical center, University of Ulsan college of Medicine, Korea

PP-082 Multi-gene sequencing of hemophagocytic lymphohistiocytosis in pediatric patients: Gene profiles and its correlation with bone marrow findings

<u>Sohee Ryu</u>¹, Sung-Min Kim², Naery Yang¹, Dajeong Jung¹, Jiwon Yun¹, Kyumin Lim², Sang Mee Hwang³, Hyoung Jin Kang⁴, Dong Soon Lee*^{1,2}

Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea

² Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

³ Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

PP-083 Isolated splenic Rosai-Dorfman disease presenting as a fever of unknown origin in a 10-months-old child

Khilola Rustamova, Kyung Mi Park, Young Tak Lim, Su Eun Park, Eu Jeen Yang*
Department of Pediatrics, Pusan National University Yangsan Hospital, Yangsan, Korea

PP-084 Multiple myeloma in teenage patient: A case report

Nguyen Phuong Dung Co*1,2, Quoc Tuan Tran¹, Thuy Duong Trinh¹

¹ Adult Hematology No.1, Blood Transfusion and Hematology Hospital in Ho Chi Minh City, Vietnam

PP-085 Multiple myeloma patients on novel agents: Effect of pneumococcal vaccination on incidence of infectious complications

<u>Igor Stoma</u>*1,², Igor İskrov¹, Irina Lendina¹, Anatoly Uss¹, Igor Karpov², Veronika Cherniak¹, Olga Gerasimovich¹, Anna Trubkina¹

¹ Department of Hematology №3, Minsk Scientific Practical Center of Surgery, Transplantation and Hematology, Belarus

PP-086 Detection of chromosome 13 (13q14) deletion among Sudanese patients with multiple myeloma using a molecular genetics fluorescent in situ hybridization

Amar Dowd^{1,}

¹ Faculty of Medicine, University of Medical Science and Technology, Sudan

PP-087 MGUS predicts worse prognosis in patients with coronary artery disease

Zhao Xu, Peng Liu*

Hematology, Zhongshan Hospital of Fudan University, China

³ Department of Laboratory Medicine, Gachon University Gil Medical center, Korea

⁴ Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea

² Hematology, Pham Ngoc Thach University of Medicine, Vietnam

² Department of Infectious Diseases, Belarusian State Medical University, Belarus

² Faculty of medical laborotary, University of Medical Science and Technology, Sudan

PP-088 The value of abdominal fat aspiration and labial salivary gland biopsy in diagnosing immunoglobulin light chain amyloidosis

Tianhong Xu¹, Peng Liu*¹, Zheng Wei¹, Chen Chen¹, Yuging Shen², Xiaowen Ge³

¹ Department of Hematology, Zhongshan Hospital, Fudan University, China

PP-089 Megakaryocytic expression of GATA-1, IL-6, and IL-8 in plasma cell neoplasm with dysmegakaryopoiesis

Hyunji Kim, Hye Ryoun Kim*

Department of Laboratory Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Korea

PP-090 Bortezomib-based first line treatment for AL amyloidosis patients who are not candidate for stem cell transplantation

<u>Joon Young Hur</u>¹, Kang Kook Lee¹, Sang Eun Yoon¹, Sehhoon Park¹, Jangho Cho¹, Youjin Kim¹, Gayeon Lee², Jinoh Choi², Eunseok Jeon², Ju Hong Min³, Byungjun Kim³, Jung Sun Kim⁴, Jung Eun Lee⁵, Joon Young Choi⁶, Seok Jin Kim¹, Jun Ho Jang¹, Won-Seog Kim¹, Chul Won Jung¹, Kihyun Kim^{*1}

¹ Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

PP-091 Health-related quality of life in relapsed/refractory multiple myeloma: Systematic review of randomized control trials

Ambrish Singh*1, Anirudh Kotlo2

PP-092 Prognostic impact of frailty in transplant-ineligible multiple myeloma patients treated with first-Line bortezomib-based chemotherapy

<u>Ji Hyun Lee</u>¹, Sung-Hyun Kim¹, Seok Jae Huh¹, Jae-Cheol Jo², Ho-Jin Shin³, Won-Sik Lee⁴, Yoo Jin Lee⁵, Ho Sup Lee^{*6}

² Department of Stomatology, Zhongshan Hospital, Fudan University, China

³ Department of Pathology, Zhongshan Hospital, Fudan University, China

² Division of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

³ Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

⁴ Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

⁵ Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

⁶ Departement of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

¹ Independent Researcher, Delhi, India

² Global Health, Fairleigh Dickinson University, Vancouver, British Columbia, Canada

¹ Department of Internal Medicine, Dong-A University College of Medicine, Korea

² Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Korea

³ Department of Hematology and Oncology, Busan National University Hospital, Korea

⁴ Department of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Korea

⁵ Department of Internal Medicine, Kyungpook National University School of Medicine, Korea

⁶ Department of Hematology and Oncology, Kosin University Gospel Hospital, Korea

PP-093 Comparison of conventional cytogenetic analysis and fluorescence in situ hybridization in survival of newly diagnosed myeloma patients

 $\underline{\text{In Hwa Jeong}}, \text{Gyu Dae Ahn, Hyeon Ho Lim, Kwang Sook Woo, Kyung Hee Kim, Jeong Man Kim, Jin Yeong Han*}$

Laboratory Medicine, Dong-A University Hospital, Korea

PP-094 Orthotopic heart transplant facilitated autologous hematopoietic stem cell transplantation for light-chain amyloidosis

Rt Kamble*1, G Obi1, A Scholoff1, L Rice2, A Bhimraj3, Jd Estep3, B Trachenberg3, G Carrum1

¹ Center for Cell and Gene Therapy, Baylor College of Medicine, USA

PP-095 Changes in blood viscosity and yield stress before and after phlebotomy

Mikyoung Park, Mina Hur*, Sumi Yoon, Hanah Kim, Hee-Jung Chung, Hee-Won Moon, Yeo-Min Yun Department of Laboratory Medicine, Konkuk University School of Medicine, Korea

PP-096 Do we need the revised 2016 WHO polycythemia vera diagnostic criteria for better diagnosis of posttransplantation erythrocytosis?

<u>Myung-Won Lee</u>¹, Hyewon Ryu¹, Yoon-Seok Choi¹, Ik-Chan Song¹, Hyo-Jin Lee¹, Hwan-Jung Yun¹, Deog-Yeon Jo*¹, Dae Eun Choi², Ki-Ryang Na², Kang Wook Lee²

¹ Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, Chungnam National University, Korea

² Division of Nephrology, Department of Internal Medicine, College of Medicine, Chungnam National University, Korea

PP-097 Characteristics and survival of atypical chronic myeloid leukemia; Based on national health information database

<u>Jee Hyun Kong</u>*¹, Tae-Hwa Go², Jung Yeon Lee¹, Shin Young Hyun¹, Seung Taek Lim¹, Kwang Yong Shim¹, Jong In Lee¹

¹ Division of Hematology-Oncology, Division of internal Medicine, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Korea

² Center of Biomedical Data Science, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Korea

PP-098 Clinical application of next-generation sequencing in myeloproliferative neoplasms: Genetic profiles and prognostic significance

<u>Jong-Mi Lee</u>^{1, 2}, Eunhee Han^{1, 2}, Kyungja Han^{1, 2}, Ki-Seong Eom³, Yonggoo Kim^{1, 2}, Myungshin Kim^{*1, 2} ¹ Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

² Catholic Genetic Laboratory Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

³ Division of Hematology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

² Hematology, Houston Methodist Hospital, USA

³ Cardiology, Houston Methodist Hospital, USA

PP-099 Clinical effect of haploidentical hematopoietic stem cell transplantation combined with posttransplant cyclophosphamide for children with severe aplastic anemia

Yan Yue, Xiaodong Shi*

Hematology and Oncology, Capital Institute of Pediatrics, China

PP-100 The outcome of immunotherapy by antithymocyte globulin and cyclosporine a for acquired aplastic anaemia during 10 years in Vietnam

Thi Mai Huong Nguyen¹, Thi Huong Mai Nguyen², Ba Truc Duong¹, Hoang Nam Nguyen*¹

¹ Clinical Hematology, National Children's Hospital, Vietnam

² Faculty of Pediatric, Hanoi Medical University, Vietnam

PP-101 The incidence of severe chronic neutropenia in Korea and related clinical manifestations:
A national health insurance database study

Nuri Lee*1, Boung Chul Lee2

Department of Laboratory Medicine, Hangang Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

² Department of Psychiatry, Hangang Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

PP-102 CD3/CD45RA depleted haploidentical transplant for SCID: First case in Vietnam

Le Nguyen-Ngoc-Quynh

Immunology-Allergy-Rheumatology Department, National's Children Hospital, Vietnam

PP-103 Label-free and high-sensitive detection of pseudomonas aeruginosa from bacteremia using a surface plasmon resonance DNA-based biosensor

Zhenbo Xu^{1,2}

¹ School of Food Science and Engineering, South China University of Technology, China

² Department of Microbial Pathogenesis, University of Maryland, USA

PP-104 Detection of staphylococcal bacteremia virulence factors using novel isothermal amplification with SPR biosensor methodology

Junvan Liu^{1,2}

¹ South China University of Technology, School of Food Science and Engineering, China

² College of Pharmacy, University of Tennessee Health Science Center, USA

PP-105 Diagnostics under sky: Mitigation of gap in global health point-of-care diagnosis in extremely poor hematology laboratory linking frugal science

Anil Gautam*¹, Bijay Subedi², Niranjan Koirala¹, Avinash Kumar Gupta³

¹ Department of Clinical Research, Dr. Koirala Research Institute for Biotechnology, Nepal

² Department of Medical Laboratory Technology, Pokhara University, Nepal

³ Medicine and Surgery, Universal College of Medical Science, India

PP-106 Acute kidney disease as a 90-day mortality predictor in hemato-oncologic patients with persistent acute kidney injury and vancomycin treatment

Ahram Yi¹, Mina Hur*¹, Hyeong Nyeon Kim², Hanah Kim¹, Hee-Jung Chung¹, Hee-Won Moon¹, Yeo-Min Yun¹, Sung-Yong Kim³, Mark Hong Lee³

PP-107 Pattern of hematological disorders on bone marrow examination: A tertiary care hospital experience

Noorulain Fareed*, Ghulam Fatima, M. Saeed Quraishy, Tariq Mehmood
Department of Haematology, CHK-Central Laboratory, Dr. Ruth K. M. Pfau, Civil Hospital, Karachi, Pakistan

PP-108 Flow cytometry quantitation of acridine orange-Stained malaria parasites

Attakorn Palasuwan

Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Thailand

PP-109 Platelet counting in thrombocytopenic samples using mindray BC-6800 plus

<u>Sumi Yoon</u>, Hanah Kim, Mina Hur*, Hee-Jung Chung, Hee-Won Moon, Yeo-Min Yun Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea

PP-110 Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), compared with IL-1β, IL-6, TNF-A and CRP in hematologic malignancy

Jung Yoon¹, Ji-Youn Lim², Eun-Ah Chang¹, Deok-Su Kim¹, Shin-Jong Kim¹, Myung-Hyun Nam¹, Donggeun Sul², Hwa Jung Sung⁴, Ji Seon Choi³, Se Ryeon Lee⁴, <u>Chi-Hyun Cho</u>*¹

¹ Department of Laboratory Medicine, Korea University Medical College, Korea

PP-111 Cell population data of automated hematology analyzer Sysmex XN for Sepsis

Mikyoung Park, Mina Hur*, Hanah Kim, Hee-Jung Chung, Hee-Won Moon, Yeo-Min Yun Department of Laboratory Medicine, Konkuk University School of Medicine, Korea

PP-112 The effect of oral administration corticosteroid toward leukocytes number and differential count in mice (Mus Musculus) based on its duration

Handyka Milfiadi*¹, Rahmatini Rahmatini², Zelly Dia Rofinda³

¹ Department of Laboratory Medicine, Konkuk University School of Medicine, Korea

² Department of Laboratory Medicine, Samkwang Medical Laboratories, Korea

³ Department of Internal Medicine, Konkuk University School of Medicine, Korea

² Graduate School of Medicine, Korea University, Korea

³ Department of Laboratory Medicine, International St. Many's Hospital, Catholic Kwandong University College of Medicine, Korea

⁴ Department of Hematology, Korea University Medical College, Korea

¹ Faculty of Medicine, Andalas University, Indonesia

² Department of Pharmacology, Medical Faculty of Andalas University, Indonesia

³ Department of Clinical Pathology, Medical Faculty of Andalas University, Indonesia

DD 44	A 1.1			1	c	
PP-11	Hemato	odic scoring	i svistam to	r detection o	t neonatal	CANCIC
	U I ICITIALO	OGIC SCOTTING	1 3 4 3 (n acticition o	i i iCOi iatai	20013

Siti Anisa Fatmawati

Clinical Pathology/Laboratory, Fatimah Islamic Hospital, Indonesia

PP-114 Screening of dysplastic neutrophils using cell population data using Sysmex XN-1000 analyzer Hyunjung Kim, Eunhee Han, Kyungia Han*

Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

PP-115 A case of spurious white blood cell count from automated Sysmex XN hematology analyzer: Difference between WNR and WDF channels

Han Joo Kim, Seung Namgoong, Chan-Jeoung Park*

Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center, Seoul, Korea

PP-116 Atypical chronic lymphocytic leukemia has a worse prognosis than CLL and clinically and laboratory different from B-cell prolymphocytic leukemia

<u>Ari Ahn</u>¹, Chan-Jeoung Park*¹, Eul-Ju Seo¹, Seongsoo Jang¹, Young-Uk Cho¹, Misuk Ji², Youn Mi Choi², Kyoo-Hyung Lee³, Jae-Hwan Lee³, Jung-Hee Lee³, Dok Hyun Yoon³, Cheol Won Suh³

¹ Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea

PP-117 Participation in the external quality assurance for international normalised ratio: Our experience

Halimatun Radziah Binti Othman*, Fatmawati Kamal

Department of Pathology, Faculty of Medicine Universiti Teknologi MARA Sungai Buloh Campus, Malaysia

PP-118 HDAC inhibitor martinostat-induced immunogenic cell death in chronic myeloid leukemia

Haeun Yang¹, Aloran Mazumder², Michael Schnekenburger², Marc Diederich*¹

¹ College of Pharmacy, Seoul National University, Korea

² LBMCC, Kirchberg Hospital, Luxembourg

PP-119 Optimization of high resolution melting assays for detection of candidate SNPs associated with anemia: The nutrigenomics unit, FNRI-DOST experience

<u>Vanessa Joy Timoteo</u>*^{1, 2}, Rod Erick Agarrado², Jacus Nacis², Marietta Rodriguez²

¹ Institute of Biomedical Sciences, Academia Sinica, Taiwan International Graduate Program in Molecular Medicine, Taiwan

PP-120 Comparison of gene expression profile in myeloid, lymphoblastic and mixed phenotype acute leukemia sharing minor BCR/ABL1 fusion using RNA sequencing

<u>Jaewoong Lee^{1,2}</u>, Eunhee Han^{1,2}, Kyungja Han¹, Seong-Eui Hong³, Byung-Sik Cho⁴, Hee-Je Kim⁴, Myungshin Kim^{1,2}, Yonggoo Kim^{1,2}

² Laboratory Medicine, VHS Medical Center, Seoul, Korea

³ Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea

² Nutrigenomics Unit, Food and Nutrition Research Institute, Department of Science and Technology, Philippines

Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Korea

² Catholic Genetic Laboratory Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea ³ TheragenETEX Co. LTD, Korea

⁴ Department of Hematology, Leukemia Research Institute, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Korea

PP-121 Synergistic apoptosis induced by a targeted combination treatment with midostaurin and ABT199 in the FLT3-ITD-Positive and BCL2-overexpressing MV4-11

Marc Diederich*, Somi Lee

College of Pharmacy, Seoul National University, Korea

PP-122 TMQ0153, a synthetic hydroquinone, induces autophagy followed by controlled necroptosis via mitochondrial dysfunction in chronic myelogenous leukemia

Sungmi Song¹, Barbora Orlikova^{1,2}, Claudia Cerella^{1,2}, Ali Al-Mourabit³, Marc Diederich*¹

¹ College of Pharmacy, Seoul National University, Korea

PP-123 Burden and associated factors of anemia among pregnant women attending antenatal care in southern Ethiopia: Cross sectional study

Amare Desalegn Wolide

Medical Physiology Department, Jimma University, Ethiopia

PP-124 Molecular genetic modifier of glucose-6-phosphate dehydrogenase gene

Pornlada Nuchnoi*^{1,2}, Usanee Kerdpin³, Virapong Prachayasittikul², Chartchalerm Isarankura-Na-Ayudhya² Department of Clinical Microscopy, Faculty of Medical Technology, Faculty of Medical Technology, Mahidol University, Thailand

² Center for Research and Innovation, Faculty of Medical Technology, Mahidol University, Thailand

PP-125 Macrocytic anemia associated infantile tremor syndrome and vitamin D

Gemawat Narendra

Pediatrics, Hindustan Chamber Chikitsalaya, India

PP-126 Smartphone-based diagnosis in glucose-6-phosphate dehydrogenase deficiency

Attakorn Palasuwan

Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Thailand

PP-127 Microparticles-derived miRNAs serves as a novel diagnosis marker for glucose-6-phosphate dehydrogenase deficiency

Duangdao Palasuwan

Clinical Microscopy, Chulalongkorn University, Thailand

PP-128 Association of hematologic parameters with TMPRSS6 gene variations in iron deficiency anemia patients

Javad Alizargar

Medicine, Kashan University of Medical Sciences, Iran

² Laboratory of Molecular and Cellular Biology of Cancer, LBMCC, Luxembourg

³ ICSN-CNRS, LabEx LERMIT Centre de Recherche de Gif-Sur-Yvette, France

³ Department of Chemistry, Faculty of Science, Naresuan University, Thailand

PP-129 The effect of moringa seeds extract as anti anemia of chronic disease through decreasing IL-6 expression in liver tissue of metabolic syndrome rats

Mohamad Arif Fikri*, Bastomy Eka Rezkita Pathology Anatomy, Sebelas Maret university, Indonesia

PP-130 Thalassemia major patients presenting with raised HbF and a fast moving Hb

Rakesh Kumar¹, Chandan S. Sagar¹, Dharmesh, C. Sharma², Purnima Kishor* ¹ School of Studies in Biochemistry, Jiwaji University, Gwalior,Madhya Pradesh, India

² Blood Bank, Jayarogya Hospital, Gajra Raja Medical College, Gwalior, Madhya Pradesh, India

PP-131 Exploring the β-thalassaemia mutations in western rajasthan with clinical expression

Abhishek Purohit*¹, Kuldeep Singh², Anand Raj Kalla³, Manju Bohra⁴, Deepak Vedant¹, Mayank Kumar¹, Shashikant Saini⁵

¹ Pathology, All India Institute of Medical Sciences, Jodhpur, India

³ Pathology, Dr. S N Medical College, Jodhpur, India

⁴ Immunohaematology and Blood TRansfusion, Dr. S N Medical College, Jodhpur, India

⁵ All India Institute of Medical Sciences, Jodhpur, India

PP-132 A case of δ-Thalassemia in Korea

Boram Kim¹, Seok II Hong², Ji Ae Lim², Sung Sup Park¹, Han-Ik Cho*² Department of Laboratory Medicine, Seoul National University Hospital, Korea

² Medicheck Laboratory, Korea Association of Health Promotion, Korea

PP-133 Parvovirus B19-associated neutropenia and thrombocytopenia without anemia

Hyoshim Shin¹, Sungwoo Park², Gyeong-Won Lee^{2,3}, Eun-Ha Koh^{1,3}, Hyun-Young Kim*¹ Department of Laboratory Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea

² Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea

³ Institute of Health Science, Gyeongsang National University, Jinju, Korea

PP-134 Attenuation of anemia by retnla in LPS-induced inflammatory response

Mi-Ran Lee*, Seon-Hye Lee, Min-Ju Jeung, Yoon-Hee Hwang, Nam-Hee Kim, Yoon-Jin Park Department of Biomedical Laboratory Science, Jungwon University, Korea

PP-135 Glucose-6-phosphate dehydrogenase deficiency in newborns in Birjand, Iran

Mohammad Sadegh Kamali¹, Mohammad Hossein Motahari Nasab¹, Seved Mehdi Saiiadi^{*2}

Student Research Committee, Biriand University of Medical Sciences, Biriand, Iran

² Paediatrics, All India Institute of Medical Sciences, Jodhpur, India

² Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran

PP-136 Screening of α-thalassemia using cord blood in Bangladesh

Saeed Anwar, Md. Farugue Miah*

Department of Genetic Engineering and Biotechnology, School of Life Sciences, Shahjalal University of Science and Technology, Bangladesh

PP-137 Knowledge trend of anemia in adolescents in Indonesia

Nuraliah Nuraliah

Faculty of Health, West Sulawesi University, Indonesia

PP-138 Successful sirolimus treatment of pure red cell aplasia in patients with renal insufficiency

Zesona Chen, Bina Han*

Department of Hematology, Peking Union Medical College Hospital and Peking Union Medical College, China

PP-139 Local wisdom and anemia prevention: Study of the use of herbs as an alternative treatment for rural communities in west Sulawesi. Indonesia

Mahvuddin Mahvuddin

Faculty of Social and Governmental Science, University of Al Assyariah Mandar, Indonesia

PP-140 The influence of socio-economic factors on prevelence of anemia among women of reproductive age in ASEAN-5

Putri Avu

Economics of Development, Universitas Andalas, Indonesia

PP-141 The problem of identification of population objects during the unification of data from multiple sources when working with a hemophilia register

<u>Saidrakhim Lukmonov</u>*¹, Uktam Kurbankulov¹, Sergey Kim¹, Akbar Abdullaev²

PP-142 Prevalence of anaemia in western region of Nepal: A hospital based study

Mukunda Raj Kalouni, Saroj Pokhrel*

Clinical Pathology, Manipal Teaching Hospital, Nepal

PP-144 Chlorophyll as a considerable treatment for anemia through increases hemoglobin levels in anemia white rat model

Indah Sagitaisna Putri*, Faisal Hafidh

Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia

PP-145 Effect of carica papaya leaf extract on platelet counts in patient of dengue

Jay Karan*1, Pankaj Bhardwaj2, Jagdish Goyal3

¹ Hematology, Tashkent Medical Academy, Uzbekistan

² Hematology, Samarkand State Medical Institute, Uzbekistan

¹ Pharmacology, All India Institute of Medical Sciences, Jodhpur, India

² Community and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India

³ Paediatrics, All India Institute of Medical Sciences, Jodhpur, India

PP-146 Platelet indices and their value in differentiating the causes of thrombocytopenia

<u>Thi Duyen Nguyen</u>, Thi Nghiem Luong* *Hematology, National Children's Hospital, Vietnam*

PP-147 Perioperative management and outcomes in children with congenital bleeding disorders:

A retrospective review at a single hemophilia treatment center

<u>Ha Nuel Chon</u>, Seoin Kim, Jinjoo Kim, Young Shil Park* Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Korea

PP-148 Reference intervals for platelet dense granules using whole mount electron microscopy

Jin-Yeong Han*¹, In-Hwa Jeong¹, Hee-Won Chueh², Sang-Soo Park³, Seo-Hee Rha³

¹ Department of Laboratory Medicine, Dong-A University College of Medicine, Korea

PP-149 Platelet parameters and inflammation in anemic and non-anemic patients with type 2 diabetes and early CKD

Ivan Pchelin*¹, Alexander Shishkin¹, Valentina Bayrasheva², Natalia Hudiakova¹

PP-150 Parameters of coagulation and fibrinolysis in patients with diabetes type 2 and chronic kidney disease

<u>Volha Vasilkova</u>*¹, Tatsiana Mokhort², Yana Borovets¹, Ludmila Korotaeva⁴, Natallia Filiptsova³, Elena Naumenko³

PP-151 The prognostic value of mean platelet volume in venous thromboembolism

Atika Budhy Setyani*¹, Muhamad Fajri Addai², Jonathan Hasian Haposan³

PP-152 The prognostic role of red cell distribution width in venous thromboembolism and related mortality

Muhamad Fajri Addai*¹, Atika Budhy Setyani², Jonathan Hasian Haposan³, Amiliana Mardiani Soesanto⁴

² Department of Pediatrics, Dong-A University College of Medicine, Korea

³ Department of Pathology, Dong-A University College of Medicine, Korea

¹ Department of Faculty Therapy, Saint Petersburg State University, Russia

² Institute of Endocrinology, Almazov National Medical Research Centre, Russia

¹ Endocrinology, Gomel State Medical University, Belarus

² Endocrinology, Belarussian State Medical University, Belarus

³ Functional Diagnostics, The Republican Research Center for Radiation Medicine and Human Ecology, Belarus

⁴ Laboratory Diagnostics, The Republican Research Center for Radiation Medicine and Human Ecology, Belarus

Emergency Department, Cempaka Putih General Hospital, Jakarta, Indonesia

² Emergency Department, Johar Baru Primary Health Care, Jakarta, Indonesia

³ Department of Epidemiology, University of Pittsburgh, USA

¹ Emergency Department, Johar Baru Primary Health Care, Jakarta, Indonesia

² Emergency Department, Cempaka Putih General Hospital, Jakarta, Indonesia

³ Department of Epidemiology, University of Pittsburgh, USA

⁴ Non-Invasive Diagnostic and Echocardiography Department, National Cardiovascular Center of Harapan Kita, Indonesia

Long-term expansion of Gata1^{low} Meg-erythroid cells increased cell division while maintained PP-153 differentiation potential

Eunju Shin^{1,2}, Daseul Kim¹, Jong-Gwan Jeong¹, Haiyoung Jung¹, Suk-Ran Yoon¹, Tae-Don Kim¹, In-Pyo Choi¹, li-Yoon Noh1*

¹Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea ² College of Pharmacy, Chungnam National University, Daejeon, Korea

PP-154 Analysis of genetic factors in Korean adult patients with atypical hemolytic uremic syndrome Jae Won Yun¹, Ki-O Lee², Jung Oh Kim⁴, Nam Keun Kim⁴, Jin Seok Kim⁵, Junshik Hong⁶, Youngil Koh⁶, Sung-Soo Yoon⁶, Ho-Young Yhim⁷, Yong Park⁸, Ki Young Kwon⁹, Jinny Park¹⁰, Jong Wook Lee¹¹, Hee-Jin Kim¹, Doveun Oh*3

PP-155 Hereditary platelet function disorder from RASGRP2 mutations identified by whole exome sequencing

Jae Won Yun¹, Chul Won Jung², Soo-Young Oh³, Sun-Hee Kim¹, Chul Won Choi⁴, Hee-Jin Kim*¹ Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

² Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

PP-156 Cryopreservation of peripheral blood stem cell using mechanical freezers: Initial Experience from an Indian tertiary care hospital

Nitin Agarwal*, Prashant Pandey

Transfusion Medicine and Transplant Immunology, Jaypee Hospital, India

PP-157 Modified post-transplant cyclophosphamide allogeneic HSCT combined with decitabinebased reduction, busulfan and melphalan conditioning regimen in children with juvenile myelomonocytic leukemia

Xiaodona Shi, Yan Yue*

Hematology and Oncology, Capital Institute of Pediatric, China

Department of Laboratory Medicine and Genetics, Samsung Medical Center, Korea

² Samsung Biomedical Research Institute, Samsung Medical Center, Korea

³ Department of Internal Medicine, School of Medicine, CHA University, Korea

⁴ Department of Biomedical Science, CHA University, Korea

⁵ Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Korea

⁶ Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Korea

⁷ Department of Internal Medicine, Chonbuk National University Medical School, Korea

⁸ Department of Internal Medicine, Korea University College of Medicine, Korea

⁹ Department of Oncology-Hematology, Keimyung University College of Medicine, Korea

¹⁰ Department of Internal Medicine, Gachon University College of Medicine, Korea

¹¹ Department of Hematology, St. Mary's Hospital, College of Medicine, The Catholic University, Korea

³ Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine,

⁴ Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea

PP-158 The correlation and predictive value of immature platelet fraction to plasma platelet recovery in patients receiving autoSCT

Siew Lian Chong*¹, Kian Boon Law², Kian Meng Chang²

¹ Hematology Department, Hospital Ampang, Malaysia

² Clinical Trial Unit, National Clinical Research Centre, MOH, Malaysia

PP-159 Survival by time to start of defibrotide in veno-occlusive disease/sinusoidal obstruction syndrome post hematopoietic stem cell transplant in adults

Paul Richardson*¹, Enric Carreras², Antonio Pagliuca³, Robert Ryan⁴, William Tappe⁵, Mohamad Mohty⁶, <u>Richard Martin⁷</u>

¹ Department of Medical Oncology, Division of Hematologic Malignancy, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, USA

² Spanish Bone Marrow Donor Program, Josep Carreras Leukemia Foundation and Leukemia Research Institute, Spain

³ Department of Haematology, King's College Hospital, United Kingdom

⁴ Biostatistics, Jazz Pharmaceuticals, Inc., USA

⁵ Clinical Development, Jazz Pharmaceuticals, Inc., USA

⁶ Hematology Department, Hôpital Saint Antoine, AP-HP, Sorbonne Université, USA

⁷ Jazz Pharmaceuticals, Oxford, UK

PP-160 Initial evaluation of the efficacy of autologous stem cell transplantation in non-hodgkin lymphoma at HCMC blood transfusion hematology hospital

Nam Duy Hoang*, Thu Hanh Nguyen, Phu Duc Vinh Huynh, Man Van Huynh, Dung Chi Phu Stem Cell Transplantation Department, HCMC Blood Transfusion Hematology, Vietnam

PP-161 Evaluation of the bacterial and fungal infection status in HSCT patients in HCMC blood transfusion and hematology hospital

<u>Hanh Thu Nguyen*</u>, Van Man Huynh, Duc Vinh Phu Huynh, Duy Nam Hoang, Thien Ngon Huynh, Xuan Tuan Ma, Chi Dung Phu

Stem Cell Transplantation Department, Blood Tranfusion Hematology Hospital, Vietnam

PP-162 Recovery of specific subsets of NK and T cells highly associated with GVHD after haploidentical stem cell transplantation in acute leukemia

<u>Haerim Chung</u>¹, Ji Eun Jang¹, Yu Ri Kim¹, Hoi-Kyung Jeung², Ju-In Eom², Soo-Jeong Kim¹, Jin Seok Kim¹, June-Won Cheong¹, Yoo Hong Min*¹

Department of Internal Medicine, Yonsei University College of Medicine, Korea

PP-163 Autologous hematopoietic stem cell transplantation in acute myeloid leukaemia: Long-term outcome

Azizan Sharif^{* 1}, Tan Sen Mui ¹, Ong Tee Chuan ¹, Ho Kim Wah ¹, Sharifah Shahnaz Syed Abdul Kadir ¹, Law Kian Roon ²

² Avison Biomedical Research Center, Yonsei University College of Medicine, Korea

¹ Department of Hematology, Hospital Ampana, Malaysia

² Clinical Research Centre, Hospital Ampang, Malaysia

PP-164 Impact of CMV prophylaxis on rates of rehospitalization in adult CMV seropositive allogeneic HSCT recipients: Experience from the letermovir phase 3 clinical trial

Shahrul Mt-Isa*, Hong Wan, Cyrus Badshah, Valerie Teal, Randi Leavitt, Jonathan Schelfhout, <u>Eungeol Sim</u> Merck & Co. Kenilworth, NJ. USA

PP-166 Lkb1 modulates regulatory T cell homeostasis during acute GVHD

Xiuhua Su, Erlie Jiang*

Hematopoietic Stem Cell Transplantation Center, Institute of Hematology, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China

PP-167 Phase II study of imatinib mesylate and mycophenolate mofetil in children with steroidrefractory sclerotic type chronic graft-versus-host disease

<u>Jung Yoon Choi</u>¹², Hyery Kim³, Hyoung Jin Kang*¹², Hee Jo Baek⁴, Hoon Kook⁴, Jae Min Lee⁵, Hong Yul An¹², Kyung Taek Hong¹², Hee Young Shin¹²

PP-168 Role of platelet-rich plasma in healing diabetic and leprosy foot ulcers in resource poor setting Shambhu Dutta Joshi

Dermatology, Far western Community Hospital, Nepal

PP-169 Curative effect and optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome of higher risk groups

Oiangian Wang, Mingzhe Han*

Department of Hematopoietic Stem Cell Transplantation, Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, China

PP-170 Renal parameters and their associations with clinical severity score among adult Sudanese patients with sickle cell anemia

Mohamed Suliman*¹, Alnazeer Hassan², Lamis Kaddam³

PP-171 Autonomic activity and haemodynamic characteristics in relation to clinical severity of sickle cell anaemia among steady state adults

Alnazeer Hassan*¹, Mohamed Suliman², Lamis Kaddam³

¹ Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea

² Seoul National University Cancer Research Institute, Seoul, Korea

³ Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, Seoul, Korea

⁴Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea

⁵ Department of Pediatrics, College of Medicine, Yeungnam University, Daegu, Korea

¹ Physiology, Ibn Sina University, Sudan

² Physiology, Al-Fair College, Sudan

³ Physiology, Al Neelain University, Sudan

¹ Physiology, Alfajr College for Science and Technology, Sudan

² Physiology, Ibn Sina University, Sudan

³ Physiology, Alneelain, Sudan

PP-172 A somatic cell nuclear transfer methodology for replacement of hematological malignant cells population in the myeloproliferative disorders

Abdul Mannan Baig

Biological and Biomedical Sciences, Aga Khan University, Pakistan

PP-173 Adipose-derived stem cells therapy in diabetic osteoarthritis

Navneet Kumar Dubey*1, Win-Ping Deng2

[†] Ceramics and Biomaterials Research Group, Advanced Institute of Materials Science, Ton Duc Thang University, Ho Chi Minh City, Vietnam

² School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan

Adipose tissue derived stromal-vascular-fraction enriched platelet-rich-plasma therapy PP-174 reverses the effects of androgenetic alopecia

Mahmood Saba* 1,2,3

Department of Dermatology, King Edward Medical University, Pakistan

² Biomedical Sciences, Kina Edward Medical University, Pakistan

³ Tissue Engineering and Regenerative Medicine Laboratory, Department of Biomedical Sciences, King Edward Medical University, Lahore, Pakistan

PP-175 To determine the frequency and types of RBC alloimmunization in multitransfused oncology patients at a teaching hospital in Lahore, Pakistan

Aisha Mahesar*, Ayisha Imran, Nauman Malik, Mansoor Mazari

Hematology, Chughtais Lahore Lab, Pakistan

PP-176 An attempt to tailor wastage of blood products in the form of returned units

Sidra Asad Ali¹, Maria Ali², Huma Mansoori³

Laboratory, Patel Hospital, Pakistan

² Pathology, Jinnah Medical and Dental College, Pakistan

³ Pathology, Dow University of Health Sciences, Pakistan

PP-177 Inappropriate use of fresh frozen plasma in a tertiary care hospital

Sidra Asad Ali*, Wajeeha Noman, Mariam Mirza Laboratory, Patel Hospital, Pakistan

PP-178 Post donation notification, counseling and response rate of reactive blood donor:

An important step to prevent reactive donor from re-donating blood

Sidra Asad Ali*, Syed Usama, Mariam Mirza

Laboratory, Patel Hospital, Pakistan

PP-179 Therapeutic plasma exchange in rat killer (Yellow Phosphorus) poisoning: Experience from South India

<u>Deepti Sachan*</u>¹, Ilankumaran Kaliamoorthy², Akila Rajakumar², Dinesh Jothimani², Mettu S Reddy², Kulaseharan Vh², Mukul Vii³. Mohamed Rela²

PP-180 Correlation between the IgG subclasses with occurrence and severity of haemolytic disease of foetus and newborn

Rahul Katharia*, Bharat Singh, Madhkani Pradhan, Rajendra Chaudhary
Transfusion Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, INDIA, India
Maternal and Reproductive Health, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, INDIA, India

PP-181 Overview of antibodies implicated in delayed hemolytic transfusion reaction

Rahul Katharia*, Rajendra Chaudhary

Transfusion Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

PP-182 Retrospection of anti-blood group antibody proficiency testing data using geometric mean and standard deviation

<u>John Jeongseok Yang</u>, Dae-Hyun Ko*, Sang-Hyun Hwang, Heung-Bum Oh Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Korea

PP-183 Ensuring standard transfusion practices amidst staff nurses by implicating a framework of knowledge gap analysis and subsequent reformatory measures

Maria Ali Soomro*¹, Mahadev Harani¹, Sidra Asad Ali², Huma Mansoori³

PP-184 Knowledge, attitudes and practices on blood transfusion of medical residents in a tertiary hospital: A questionnaire-based study

Rmin Sheila Miranda

Internal Medicine, Philippine General Hospital, Philippines

PP-185 Correlation between packed red cells hematocrit with post-transfusion hemoglobin level in anemic patient at Badung mangusada district hospital, Bali

<u>Ni Gusti Ayu Arini Junita Putri Kardina</u>l*¹, Ni Made Renny Anggreni Rena², Wayan Losen Adnyana², Tjokorda Gde Dharmayudha², Ketut Suega², I Made Bakta², Anak Agung Wiradewi Lestari³

¹ Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Udayana University / Sanqlah General Hospital, Indonesia

¹ Transfusion Medicine, Dr. Rela Institute & Medical Centre, India

² Institute of Liver Disease & Transplant Centre, Dr. Rela Institute & Medical Centre, India

³ Department of Pathology, Dr. Rela Institute & Medical Centre, India

¹ Department of Pathology, Jinnah Medical and Dental College, Karachi, Pakistan

² Department of Pathology, Patel Hospital, Karachi., Pakistan

³ Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan

² Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Udayana University / Sanalah General Hospital, Indonesia

³ Department of Clinical Pathology, Faculty of Medicine, Udayana University / Sanglah General Hospital, Indonesia

PP-186 Impact of voluntary non-remunerated blood donation: How the community responses in developing country

Joshi Mandeep

Public Health, Community Health and Environmental Society, Nepal

PP-187 Development of deep vein thrombosis after achieving remission in a patient with acquired hemophilia A

<u>Camille Ariadne Tanchanco</u>*¹, Valerie Ramiro², Johannes Paolo Cerrado³, John Mark Torres³, Teresita Dumagay¹, Angelina Mirasol¹, Teresa Abola²

PP-188 Successful management and delivery in a pregnancy with secondary evans syndrome from systemic lupus erythematosus and antiphospholipid syndrome

Camille Ariadne Tanchanco*¹, Honorata Baylon¹, Aubrey Seneris², Patricia Pauline Remalante³, Raquel Isabelle Donado4

PP-189 On-demand versus low dose factor VIII prophylaxis treatment in hemophilia A patients: Differences in outcome and factor concentrates utilization

Kuo Zang Wong¹, Ngee Siang Lau²

PP-190 Evaluation of bone marrow study in patients with ewing sarcoma/primitive neuroectodermal tumors at a tertiary-care hospital

Kuenyoul Park¹, Min Young Lee¹, Ari Ahn¹, Hyeri Kim², Kyung-Nam Koh², Young-Uk Cho¹, Seongsoo Jang¹, Chan-Jeoung Park*1

PP-191 Bone marrow findings of IgG4-related disease; A case of bone marrow involvement of IgG4related disease

Han Joo Kim¹, Enkyung You¹, Seokchan Hong², Chan-Jeoung Park*¹

Section of Hematology, Department of Internal Medicine, Philippine General Hospital, Philippines

² Section of Cardiology, Department of Internal Medicine, Philippine General Hospital, Philippines

³ Department of Internal Medicine, Philippine General Hospital, Philippines

Section of Hematology, Department of Internal Medicine, Philippine General Hospital, Philippines

² Department of Obstetrics and Gynecology, Philippine General Hospital, Philippines

³ Section of Rheumatology, Department of Internal Medicine, Philippine General Hospital, Philippines

⁴ Section of Immunology and Allergology, Department of Internal Medicine, Philippine General Hospital, Philippines

¹Department of Pharmacy, Hospital Melaka, Malaysia

² Medical Department, Hospital Melaka, Malaysia

¹ Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Korea

² Department of Pediatrics, University of Ulsan College of Medicine and Asan Medical Center, Korea

Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center, Seoul, Korea

² Division of Rheumatology, Department of Internal Medicine, University of Ulsan, College of Medicine and Asan Medical Center, Seoul, Korea

PP-192 Etiology, sensitivity profiles, clinical course of bloodstream infections in patients with hematological and oncological diseases

Senmin Chen, Sixi Liu, Xiuli Yuan, Huirong Mai, Shilin Liu, Junrong Lin, Feiqiu Wen* Hematology and Oncology Department, Shenzhen Children's Hospital, China

PP-193 Evaluation of neutrophil extracellular traps as the circulating marker for patients with cardiocerebrovascular diseases

<u>Hyeonho Lim</u>¹, Inhwa Jeong¹, Gyudae An¹, Kwangsook Woo¹, Kyeonghee Kim¹, Jeongman Kim¹, Jaekwan Cha², Moohyun Kim³, Jinyeong Han^{*1}

PP-194 Current status of Korea leukemia bank

<u>Soo-Hyun Kim</u>^{1,2}, Mi-Young Lee^{1,2}, Soo-Young Choi², Hea-Lyun Yoo², Kyung-Mi Kee², Ji-Hyung Suh², Seon Young Yang², Suna Park², Sa-Hee Park², Dong-Wook Kim*^{1,2,3}

PP-195 A report of a new NFKB1 frameshift mutation contributing to primary immunodeficiency diseases

Yan Liu, Anli Liu, Jun Peng*

Department of Hematology, Qilu Hospital, Shandong University, China

PP-196 A case of occult macrophage activation syndrome that mimics of refeactory kawasaki disease

Sang Hyun Joo, Kwang Nam Kim*

Pediatrics, Hallym University Sacred Heart Hospital, Korea

PP-197 Cutaneous manifestation among transfusion patients

Mandeep Joshi

Public Health, Community Health and Environmental Society, Nepal

PP-199 Dipeptidyl peptidas-IV inhibition and hematological effect of alkaloids rich withania somnifera extract in type 2 diabetic mellitus; In-Vitro, In-Vivo

Anand Krishna Singh

Biotechnology, Devi Ahilya University Indore, India

PP-200 Production of a chemotherapeutic enzyme drug for acute myeloid leukemia and acute lymphoblastic leukemia: L- asparaginase

Girish Pendharkar*, Sujata Umrane, Dhanashree Patil, Shweta Patil

School of Life Sciences, Kavayitri Bahinabai Chaudhari North Maharashtra University, Jalgaon, India

¹ Department of Laboratory Medicine, Dong-A University College of Medicine, Korea

² Department of Neurology, Dong-A University College of Medicine, Korea

³ Department of Internal Medicine, Dona-A University College of Medicine, Korea

¹ Korea Leukemia Bank, The Catholic University of Korea, Korea

² Leukemia Research Institute, The Catholic University of Korea, Korea

³ Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Korea

PP-201 Factors associated with quality of life in patients with leukemia

Elaheh Alizargar, Azadeh Alizargar*
Community Health Research Center, Khorasgan Azad University, Iran

PP-202 Systematic literature review and assessment of health-related quality of life in aggressive non-hodgkin lymphoma survivors

Md Azharuddin*¹, Mohammad Adil², Pinaki Ghosh³, Manju Sharma^{1,2}

Department of Pharmaceutical Medicine, School of Pharmaceutical Education and Research, Jamia Hamdard, India

PP-203 Psychosocial counseling for prevention of sickle cell in a tribal population

Suresh Gemawat

Genaral Medical Laboratory, Madan Mohan Medical and Counselling Centre, Jodhpur, India

PP-204 Incidence of cancer incidence in India: A analysis from cancer registries

Abul Kalam Najmi*1, Md Salman Hussain2, Md Sarfaraj Hussain3

¹ Department of Pharmacology, Jamia Hamdard, India

² Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, India

³ Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth, India

² Department of Pharmaceutical Medicine, Jamia Hamdard, India

³ Department of Pharmacognocy, Integral University, India

MEMO			

MEMO	

MEMO	

MEMO	

MEMO	

MEMO			
-			
•			
•			





MabThera® SC. The wait is over.



NAME OF THE MEDICINAL PRODUCT Mid-lives 1400 mg velocitor for rejection. Qualificative CoulProSymbol Led vival critarios 1400 mg/11 for distancia. Publishman MURICINAL PRODUCT Mid-lives 1400 mg velocitor for rejection. Clear to equide-cert clusive is suplemental policy florid medications. Since 1400 mg/11 for distancia. Publishman MURICINAL PROBLEM And not rejection. Clear to equide-cert clusive is suplemental policy florid medications since victoria in the respect of subsective of local and production of medication interpret. COU production of the foliation of the centre of subsection in the respect of subsection of the centre of the cen

Size itsild imposement of clinical programs may be billowed by deterioration, those patients should be cloudy munitored until tumor lysis syndrome and gulmmany influstation has been encoded or make due. Refersive who treated after complete encodition of signs and syngrams has one only-resident in general covere cyclotic eclosery optione. It is commercially produced in the complete electrical intervals of the production of production is patient. In comment to syndrome indication of production is patient, in comment to syndrome indication of production is patient, in comment to syndrome indication of production of production is patient, in comment to syndrome indication of production of pr

For more detailed product information and/or reporting product-related adverse events, Please contact Roche Korea (02-3451-3600) For the latest product information, please refer to Roche Korea website (www.roche.co.ko







TR, treatment-free remission. EMR, early molecular response. DMR, deep molecular response.

Reference 1, Tasigna Product Information 2, Hughes et al. Blood 2014 123: 1353-1360 Feb 2014 3, Hochhaus A et al. Leukemia 2017;31(7):1525-1531(Epub 2017 Feb 20).





ADCETRIS: CD30 Targeted treatment effective

IN RELAPSED OR REFRACTORY **SALCL**



86% ORR 57% CR 55.1 MONTH'S MEDIAN OS INV.C.7.3-rox estimabili

IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WITH PRIOR ASCT**



RF- Diverall, Response Rate, CR-Complete Remission, DS-Overall Surviv

ADCETRIS

- 재발성 또는 불응성의 CD30 양성인 전신역형성대세포림프종 (systemic Anaplastic Large Cell Lymphoma, SALCL)
 Brentuximab vedotin 단독요법 (2차 이상)
- 재발성 또는 불응성의 CD30 양성인 호지킨림프종 <mark>(Hodgkin Lymphoma)</mark> 중 자가조혈모세포이식 (Autologous Stem Cell Transplant, ASCT) 실패한 환자 Brentuximab vedotin 단독요법 (2차 이상), 자가조혈모세포이식 비대상환자 Brentuximab vedotin 단독요법 (<mark>3차 이상)</mark>


REFERENCE

1.Po B, et al Bernaumoh Vedant (Sch-35) in Extents With Relapsed or Reflactory systemic Anaptack Large Cell ymphoms Results of a Place I Study / Clan Own 2012, 30 2180 € 2. Pol B, et al Tive-your results of I bernaumoh vedant in patients with relapsed or reflactory systemic anaptack Large Cell ymphoms Results of Place I Study / Clan Own 2012, 30 2180 € 2. Pol B et al Tive-your results of I bernaumoh vedant in patients (with relapsed or reflactory Hodgins) ymphoms 260 voice 2013, 2018, 2189 € 4. Oren R, et al. Tive-year survival and durability results of bernaumoh vedant in patients with relapsed or reflactory Hodgins (ymphoms 8000 2016;188(12):552-566.5. 2년보급선세용7원 골로 47016-22호 오염급에서 용가운 및 방법에 관한 세부사장 중 개용 (사용 2016년 2월 1일)

유수보임 이 보이면 함께 보면 보면 보는 이 보이는 그래 가게 되었는데 되었다. 이 보다는 그래 나는 이 보다는 이



HELP YOUR PATIENTS ALONG THEIR JOURNEY



For Ph-negative relapsed/refractory B-cell precursor ALL

REACH BEYOND REMISSION. EXTEND SURVIVAL.

Significantly extend OVERALL SURVIVAL vs. chemotherapy with the power of a bispecific T-cell engaging immunotherapy

Of evaluable Ph-negative relapsed/refractory B-precursor ALL patients who received BLINCYTO® (n=271/405),

Median Overall Survival

- **7.7 months** vs. 4.0 months in the chemotherapy group (HR 0.71: 95% Cl. 0.55-0.93: *P* = 0.01)
- 11.1 months vs. 5.3 months in the chemotherapy group at 1st salvage-treatment phase (HR 0.60: 95% CI; 0.39-0.91)

Remission Rate within 12 Weeks after Treatment Initiation

- CR/CRh/CRi
- **43.9%** vs 24.6% in the chemotherapy group [Treatment difference 19.3 (95% CI, 9.9-28.7; *P* < 0.001)]
- MRD negative status among the patients who had CR/CRh/CRi
 76% vs 48% in the chemotherapy group
 [Treatment difference 28 (95% CI, 9-47)]

CR/CRh/CRi = complete remission with full, partial, or incomplete hematologic recovery

CR was defined as 5% or less bone marrow blasts and no evidence of disease and was further characterized as follows: CR with full recovery (platelet count of >100,000/µL and ANC of >1000/µL), CR with partial recovery (platelet count of >500,000/µL and ANC of >5000/µL), or CR with incomplete recovery (platelet count of >100,000/µL or ANC of >1000/µL).

which crossed the prespecified stopping boundary

eference Kantarjian H, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 2017;376:836-4;

블리사이투'주 제품요약정박

제용한 불편사이로 주의하이로로 의용하다부터는 있는 중요하는 발판에에 역에 등장이 됐는 녹음의 전구 되다고 등을 필요구를 발했으며 제, 명시용장 이 이 기계로 인데 주는 경험인의 기계적인 경우 다이 이용이 142년이 제료 의지 간단로 이용이 있다. 이 기계로 가장 등에 경우 기계로 등에 경우 기계로 등에 유리에 가장 등에 경우 기계로 등에 경우 기계로 등에 유리에 가장 등에 가장 등에 유리에 가장 등에 가장 등에 유리에 가장 하는데 가장







The Korean Society of Hematology